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Targeted Inhibition of Sp1 Transcription Factor and Anti-
angiogenesis of Human Pancreatic Cancer 
Publication No.________ 
Zhiliang Jia, Ph.D. 
Supervisory Professor: Keping Xie, M.D., Ph.D.  
Transcription factor Specificity Protein 1(Sp1) is reported to be essential for 
vascular endothelial growth factor (VEGF) constitutive expression in human 
pancreatic adenocarcinoma. The definitive role of Sp1 in angiogenesis, the 
impact of anti-angiogenic therapy on the Sp1/ VEGF signaling and the Sp1 
signaling alteration on the anti-angiogenic therapy effect are unclear. The 
understanding of Sp1 regulation on VEGF and their interactions has significant 
clinical implications. 
Sp1 and VEGF expression and microvessel density (MVD) were analyzed using 
pancreatic cancer patients specimens through immunohistochemistry staining. 
The impact of Sp1 expression alternation on angiogenesis and tumor 
progression in nude mice were determined by knockdown Sp1 with small-
interfering RNA (siRNA). Sp1 protein expression was correlated with the MVD (P 
< 0.001) and VEGF expression (P < 0.05). In mouse models, tumor progression 
and metastasis were inhibited after knockdown of Sp1 expression. The antitumor 
viii 
 
activity was correlated with the down-regulation of Sp1 downstream angiogenic 
factors caused by Sp1 knockdown. 
Sp1 and its downstream angiogenic genes expression were suppressed by 
mithramycin treatment both in vitro and in vivo. Moreover, mithramycin treatment 
reduced MVD in vivo. This was consistent with the down-regulation of VEGF, 
PDGF, and EGFR. Human xenograft pancreatic tumor growth was suppressed 
by Bevacizumab treatment. Both western blot and immunohistochemistry 
staining revealed that Sp1 and its downstream angiogenic genes expression 
were up-regulated by Bevacizumab treatment. Bevacizumab and mithramycin 
combination treatment synergistically suppressed tumor growth in vivo. This is 
correlated with the down-regulation of Sp1 and its downstream angiogenic genes 
expression. Bevacizumab treatment may trigger a positive feedback to up-
regulate angiogenic factors through Sp1 trans-activation and this mechanism can 
be diminished by mithramycin treatment. 
Combination treatment of mithramycin and tolfenamic acid which has been 
shown to facilitate Sp1 protein degradation had synergistic cell growth inhibition 
effect in vitro. In vivo, metronomic low-dose combined treatment of mithramycin 
and tolfenamic acid produced tumor suppression in mouse model. Gene 
expression analysis showed that the combination treatment synergistic down-
regulated Sp1 and its downstream angiogenic molecule VEGF. 
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In summary, experimental results and clinical research suggested that Sp1 
signaling is very important for angiogenesis of pancreatic cancer. Mithramycin 
treatment down-regulated Sp1 protein through interpose its transcription and 
decreased Sp1 downstream angiogenic genes. These down-regulations were 
correlated with the antitumor activity. Synergistic down-regulation of Sp1 and 
decreased expression of its downstream angiogenic molecules in turn significant 
reduced the angiogenic potential of pancreatic cancer cells and is an effective 
anti-angiogenesis strategy. Therefore, this study showed that Sp1 is a key factor 
of angiogenesis and manipulation of Sp1/VEGF signaling has clinical implication 
in anti-angiogenic therapy of pancreatic cancer. 
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BACKGROUND 
PANCREATIC CANCER IS A LETHAL DISEASE 
The pancreas is an organ of the digestive system. It has two major functions that 
are performed by its two components respectively. The exocrine pancreas, which 
consists of ductal and acinar elements and is about 80 percent of the organ, 
produces several enzymes that are secreted and can digest food in intestine; and 
the endocrine pancreas, which mainly consists of islets and is about 20 percent 
of the organ, makes hormones that can enter circulating system and have 
different functions [1]. Pancreas tumors may occur in exocrine part of pancreas 
(which are the classic pancreatic adenocarcinoma) or in endocrine part of 
pancreas.   
Pancreatic cancer is the eighth cause of death and the thirteenth incidence 
cancer worldwide [2, 3]. In United State, it is currently the fourth leading cause of 
cancer related deaths [3]. According to the American Cancer Society, there were 
about 42,470 new pancreatic cancer cases and about 35,240 people die from the 
disease in 2009. Age is the most important predictor of pancreatic cancer. It is 
rare before 45 and the incidence rises greatly after that [4]. The male to female 
ratio is 1.3:1. The number one risk factor of pancreatic cancer is smoking and 
diet is the second risk factor associated with this disease. Consumption of animal 
protein and fat is associated with increased risk and vegetable diet is associated 
with decreased risk [2, 4, 5]. Several medical conditions including diabetes, 
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pancreatitis, gastrectomy and cholecystectomy are also associated with 
increased risk of pancreatic cancer [6-12]. 
Because of the non-specificity and late appearance of symptom, pancreatic 
cancer is difficult in diagnosis. It is an aggressive type of tumor and the systemic 
treatments availability is limited. The five-year survival rate of pancreatic cancer 
patients is only about 5 percent and median survival duration is about 4 to 6 
months (from diagnosis to death). Most people were diagnosed at advanced 
stages [3, 13, 14]. It is highly resistant to chemotherapy and radiotherapy. The 
pancreatic cancer cells are highly metastasis in vivo, mostly to liver and lung. 
Lots of angiogenesis and invasion key regulatory molecules are reported to be 
aberrantly expressed [15, 16].  
Most of the pancreatic tumors are primary pancreas tumors including exocrine 
tumor, endocrine tumor and non-epithelial tumors. Pancreatic tumor that 
metastasizes from other organ is about 3 to 11 percent [17-19]. In pancreatic 
carcinoma, ductal adenocarcinoma is about 80 to 85 percent and 90 percent if 
the variants are included [20, 21]. The variants of ductal carcinoma may include 
adenosquamous carcinoma, which has squamous component; mucinous 
noncystic carcinoma, which has well differentiated glands that consists of more 
than 50 percent of mucinous tissue; signet-ring cell carcinoma, which consists of 
a dyshesive population of malignant cells infiltrating the pancreas and has 
cytoplasmic mucin vacuoles that compress the nucleus and is similar to signet-
ring cell carcinoma of stomach; and several other rare variants [22-24]. Besides 
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ductal adenocarcinoma, there are some other types of pancreatic tumors that 
belong to pancreatic exocrine tumor, such as acinar cell carcinoma, 
pancreatoblastoma, solid-pseudopapillary carcinoma, serious 
cystadenocarcinoma, intraductal papillary-mucinous tumor, mucinous 
cystadenoma, osteoclast-like giant cell tumor, miscellanceous carcinoma and so 
on. Pancreatic endocrine tumors are only 0.5 to 4 percent of all pancreatic 
primary tumors. Most of the pancreatic endocrine tumor occurs in adult people. It 
mainly includes insulinoma, small cell carcinoma, glucagonoma, gastrinoma and 
so on. Non-epithelial tumors have 2 types, soft tissue tumor and lymphoma. This 
dissertation focuses on pancreatic ductal adenocarcinoma angiogenesis and 
experimental therapeutics. The word pancreatic cancer in this dissertation was 
assumed to be pancreatic ductal adenocarcinoma without specific explanation 
after this point. 
Generally pancreatic cancer appears at pancreas head. It may infiltrate to 
adjacent tissue and metastasize to distance organ such as liver and lung. Based 
on its histological and cytological characteristics, it seems that pancreatic cancer 
is developed from pancreas ductal cell. But research showed each type of cells 
of pancreas has the capacity to dedifferentiate the duct like phenotype [25, 26]. 
Genetic engineered mouse models were developed and expected to give a clear 
cut answer to the cell origin of pancreatic cancer and beyond [26-29]. Besides 
this question, researches also focus on the pancreatic ductal adenocarcinoma 
precursors. Pancreatic intraepithelial neoplasm (PanIN), mucinous cystic 
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neoplasm (MCN) and intraductal papillary mucinous neoplasm (IPMN) were 
identified as pancreatic cancer precursor lesions [30-32]. PanIN that could be 
found in the pancreas smaller caliber ducts is the most extensively studied one. 
A new nomenclature for classification of duct lesion in pancreas was documented 
in 1999 and published 2001 [33]. In addition to the histological and morphological 
characters, molecular genetics changes of PanIN development were also 
documented [33, 34]. K-Ras mutation was found to be the key molecular event 
during the process [26, 35]. Among the complicated signaling network evolved in 
PanIN, a small class of molecules, such as p53 and nuclear factor κB (NF-κB), 
control the neck, which is the messenger RNA transcription, of the whole network. 
Genetic and epigenetic changed molecules and tumor environmental factors, 
such as hypoxia, acidosis and so on, directly or un-directly use one or more 
transcription factors to modulate tumor cell physiological activities. 
TRANSCRIPTION FACTOR AND CANCER BIOLOGY 
Transcription factors are protein complexes that are responsible for regulating 
gene expression in response to upstream signal [36, 37]. The regulation links cis-
acting DNA sequence and the corresponding gene expression and may be 
activation or repression. Transcriptional activation facilitates RNA polymerase 
binding to cis-acting DNA sequence. Transcriptional repression includes the 
global or local level interference with the transcription genes directly or indirectly. 
The following discussion focuses on transcriptional activation and transcription 
factor is supposed to be transcription activator without specific explanation.  
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In the genome of life, each gene has a DNA sequence called promoter. It can 
control transcription of the gene. Promoter is usually located right before the 
coding region and its length may vary in different genes. RNA polymerase needs 
to bind to promoter before the beginning of gene transcription [38, 39]. Protein 
sequence information in the gene can be transcribed into messenger RNA by 
RNA polymerase [40]. RNA polymerase II is mainly responsible for messenger 
RNA transcription. Protein synthesis of the gene is then directed by the 
messenger RNA that is carrying the information [41]. Transcription factors can 
regulate gene transcription by controlling RNA polymerase's access to the 
promoter region. To fulfill this function, transcription factors have both cis-
element recognition and transcriptional activation. Generally these two functions 
are fulfilled by different regions of the protein primary structure. 
To fulfill the functions, transcription factors must recruit themselves on promoter 
through interaction with specific DNA sequences. Generally each kind of 
transcription factor owns one and only one handful structural motifs. The motif 
that can bind to promoter is called DNA binding domain. (A protein motif is the 
small spatial part of the whole molecule.) Transcription factor may interact with 
basal factors or other proteins called co-factor by other portions. The DNA-
binding domain of a transcription factor recognizes cis-element [38]. In eukaryotic 
life form, most genes’ promoter has the “TATAA” sequence, called the "TATA 
box". It is usually located in twenty-five to thirty nucleotides before the 
transcription start site. Transcription factors that bind this sequence are called 
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TATA-binding protein (TBP). TBP is one of the most important transcription 
factors and the main component of general transcription factor TFIID [38, 42, 43]. 
Chemically, transcription factors bind cis-element using a combination 
of electrostatic and Van der Waals forces. Transcription factors’ bindings to 
promoter are sequence specific, because the combination of the chemical 
interactions of different transcription factor is specific. DNA binding domain has 
several families according to its structure character, such as helix-turn-helix, zinc 
finger, winged helix and so on [44-47]. 
The structure motif(s) of transcription factor fulfill transcriptional activation is 
called transcriptional activation domain (TAD). By analyzing the amino acid 
sequence, TAD has been classified based on the abundance of particular amino 
acid [48, 49]. In this way transcription factor are divided into glutamine rich, 
proline rich, acidic and so on. Recently, with the assistant of computational 
biology, a nine-amino-acid transcriptional activation domain (9aaTAD) defines a 
novel domain classification of the eukaryotic and yeast transcription factor family 
[50]. Most researches showed that the transcriptional activation process 
accompanied by the conformational changes of both TAD and its binding sites, 
although the initiator of the changes may not be the same side all the time [51-
54]. 
Transcription factors are important in cell cycle control, development and 
intercellular signaling transduction. Some human diseases have been the results 
of transcription factors’ mutations. Many transcription factors were found to be 
7 
 
important for tumor related signaling and were considered to be tumor 
suppressors or oncogenes. For example, over 50 percent of tumors contain 
a point-mutation or deletion mutation of the p53 gene in human species [55-57]. 
Several transcription factors, such as hypoxia inducible factor (HIF), Sp1 and so 
on, are considered to be important for tumor angiogenesis process [58-63]. 
Some of them were found to be angiogenic factor of different types of tumors 
including pancreatic cancer. 
ANGIOGENESIS AND PANCREATIC CANCER PATHOGENESIS 
Capillaries are the lifeline of all live tissue including and especially for tumor.  
Oxygen and nutritious delivery and waste removal are the basic physiological 
function of blood circle system fulfilled ultimately by capillaries. Additionally, 
tumor needs to be near capillaries to metastasize to distance, which leads to its 
fatality property. Due to the high proliferation rate of tumor cells, tumor keeps on 
expansion and invading the around normal tissue. This process totally relies on 
the growth of new blood vessels. The physiological process of the new blood 
vessels growth from the existing vessel is called angiogenesis [64-66]. There are 
two types of angiogenesis. One is sprouting angiogenesis and the other is 
intussusceptive angiogenesis. Sprouting angiogenesis enables entire new 
vessels to grow from existing blood vessel and occurs at a rate of several 
millimeters per day. While intussusceptive angiogenesis actually form new blood 
vessel through splitting the existing blood vessel and is also called splitting 
angiogenesis [67]. But it is important because it allows a vast increase in the 
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number of capillaries with relative limited number of endothelial cells. When there 
are not enough resources especially during the embryonic development, it is a 
very important way to develop new vessels.  
The concept of angiogenesis appears in early 1970’s. It was recognized during 
the research of neoplastic as well as non-neoplastic diseases such as psoriasis, 
atherosclerosis, rheumatoid arthritis, infantile harmangioms and so on [68-73]. 
Angiogenesis occurs in not only the pathological process but also the normal 
physiological processes including reproduction, development and wound healing. 
The following discussion will focus on tumor related pathological process. 
Pathological angiogenesis may lead to bleeding, vascular leakage and tissue 
destruction. 
Angiogenesis is a process orchestrated by a lot of angiogenic factors as well as 
angiogenic inhibitors. With the progress of angiogenesis research, lots of natural 
angiogenic inhibitors were found and the concept of anti-angiogenic therapy also 
sprouted and grew rapidly especially at the mid 1990’s [74-81]. Considering the 
fact that angiogenesis is important to tumor growth and metastasis, anti-
angiogenic therapy may be one potential selection of pancreatic cancer patients. 
It may produce enhanced efficacy and long-term survival [66, 82, 83]. The 
acquisition of angiogenic phenotype of tumor tissue and its following 
maintenance are mainly through over-expression of angiogenic molecules. The 
over-expression of the molecules is activated by growth factors, stress factors 
and cytokines secreted by tumor cells. Transcription factors between the 
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upstream signal factors and downstream angiogenic factors are the neck part of 
the regulatory pathway of tumor angiogenesis and maybe a good target [58]. 
To achieve effective treatment modalities of pancreatic cancer, new targets need 
to be identified. It is crucial to fully understand the cellular and molecular 
mechanisms of the development and progression of tumor angiogenesis. Lots of 
the reported angiogenic and anti-angiogenic factors released by tumor and host 
cells are the potential targets [58, 84, 85]. Angiogenesis process is regulated by 
the interaction of these factors and then regulates the survival and metastasis of 
pancreatic tumor [58, 86, 87]. Among the numerous angiogenic factors 
discovered till now, studies have identified vascular endothelial growth factor as a 
key mediator of tumor angiogenesis in most tumor types [88-90]. Other identified 
angiogenic factors include platelet-derived growth factor (PDGF) and PDGF 
receptor [91, 92], fibroblast growth factors (FGF) and their receptors [93, 94], 
epidermal growth factor (EGF) family and their receptors [84, 95], insulin-like 
growth factor-I (IGF-I) and IGF-I receptor [96, 97], and hepatocyte growth factor 
(HGF) and the receptors, such as Met [98, 99].  
HYPOTHESIS AND SPECIFIC AIMS 
Several laboratories including ours reported that transcription factor Sp1 is an 
important angiogenic molecule in several tumor types [61, 100-104]. Sp1 is a 
zinc finger protein, and it is essential to the trans-activation of many genes that 
contain GC boxes or GT boxes (also called Sp1 site) in their promoters.  Sp1 has 
been considered to be a basal transcription factor because of its constitutive 
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expression; however increasing evidence suggests that several of biological 
functions are regulated by Sp1, such as cell growth, survival, and differentiation. 
These biological functions are closely related to tumor development and 
progression [105, 106]. It has been reported by our lab that Sp1 over-expression 
is correlated with the angiogenesis and poor prognosis of human gastric and 
pancreatic cancer [60, 61, 107-109]. With these experimental evidences, I 
hypothesize that transcription factor Sp1 is an effective target of anti-
angiogenic therapy in human pancreatic cancer. To test this hypothesis, I 
propose the following specific aims:  
1. Determine the definitive role of Sp1 in pancreatic cancer 
angiogenesis. To fulfill this aim, first whether Sp1 expression is correlated with 
angiogenic phenotype in human pancreatic cancer patient will be determined by 
state-to-art immunohistochemistry technique and corresponding statistics. 
Second, Sp1 function in pancreatic cancer angiogenesis will be defined with both 
molecular biology and cellular biology technology. 
2. Design and test anti-Sp1 targeting therapy effect and Sp1 function in 
the up-to-date anti-VEGF targeting therapy in human pancreatic cancer. 
First, Sp1 inhibitor mithramycin function will be defined to determine whether Sp1 
manipulations will improve those current regimens of pancreatic cancer therapies 
in mouse model. Second is to determine VEGF neutralization monoclonal 
antibody Bevacizumab therapy effect and optimize mithramycin and 
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Bevacizumab combination treatment in mouse model. Third, the underling 
mechanism of the anti-angiogenic therapy will be explored. 
3. Determine therapeutic effect of combined transcriptional repression 
and protein degradation of Sp1 for treatment of pancreatic cancer in mouse 
models. First is to determine the ability of mithramycin and/or tolfenamic acid to 
manipulate Sp1 in vitro. Second, therapeutic effect of mithramycin and/or 
tolfenamic acid will be determine on pancreatic cancer with mouse model. Third, 
the corresponding molecular mechanism of the anti-Sp1 anti-angiogenesis 
therapy will be explored. 
In summary, this study will be to determine the definitive role of transcription 
factor Sp1 in human pancreatic cancer and to design and test anti-Sp1 targeting 
therapy in mouse models. The long-term goal of the study would be to translate 
the therapeutic designs to clinic and benefit pancreatic cancer patients.  
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CHAPTER I 
Definitive Role of Sp1 in Pancreatic Cancer Angiogenesis 
INTRODUCTION 
PANCREATIC CANCER ANGIOGENESIS 
Just like in most solid tumors, angiogenesis plays important roles in both 
pancreatic tumor growth and metastasis. A range of angiogenic factors regulates 
angiogenesis process [82, 88, 90]. VEGF, PDGF and bFGF were considered to 
be the most important molecules among the various of angiogenic factors [82]. In 
pancreatic cancer, VEGF family was the most important angiogenic factor and 
has been well documented [88-90]. VEGF family has 6 members (Figure1), 
VEGF or VEGF-A (located on 6p12-p21) [110], VEGF-B (located on 11q13) 
[111], VEGF-C (located on 4q34) [112], VEGF-D (located on Xp22.31) [113], 
VEGF-E (found in virus ) [114], and placenta growth factor (PlGF, located on 
14q24-q31) that is 53% identity to the platelet-derived growth factor-like region of 
VEGF-A [115]. VEGF-A is the most well-characterized member and has at least 
6 isoforms. The gene coding region spans 14kb and has 8 exons (exon 6 and 7 
are the membrane binding domain) [116, 117]. VEGF189 and VEGF206 anchor in 
the membrane and stay in the extracellular matrix. VEGF165 (without exon 6) can 
be secreted or membrane bonded. VEGF121 (without exon 6 and 7) is a free 
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diffusible protein. VEGF121 and VEGF165 bind to and activate VEGFR-2 to induce 
mitogenic and permeability-enhancing. Others only work on permeability-
enhancing. VEGF-B has 2 isoforms, VEGF167 and VEGF186[118]. They can all 
form heterodimer with VEGF-A. VEGF-C and D are more selective growth factors 
for endothelium and lymphatic vessels by binding VEGFR-3.  
VEGF family members release their signal by binding VEGF receptor in the cell 
surface [119]. There are 5 VEGF receptors (Figure1), 2 of them were identified 
from endothelial cells first. They are the 180kDa fms-like tyrosine kinase 1 (Flt1 
or VEGFR1) and the 200kDa kinase insert domain receptor (KDR or VEGFR2). 
VEGFR2 binds VEGF-A, VEGF-C, VEGF-D, VEGF-E, whereas VEGFR1 binds 
VEGF-A, VEGF-B and PlGF. They are expressed mainly on vascular cell of 
endothelial origin. The third receptor is the 180kDa Flt4 (or VEGFR3). It binds 
VEGF-C and VEGF-D. Similar to VEGFR2, VEGFR3 is mainly expressed on 
endothelial cell during early development of embryo [120, 121]. However its 
expression is mostly limited to lymphatic endothelial cell in the differentiated 
tissues [122]. The other two receptors were the 130-140kDa isoforms Neuropilin-
1 (brief as NRP-1), Neuropilin-2 (brief as NRP-2). NRP-1 can bind VEGF165, and 
PlGF. NRP-2 is similar to NRP-1 and can bind VEGF165, VEGF145, PlGF and 
VEGF-C. NRP-1 and 2 are different from other family members [123]. They have 
a short intracellular domain.  The short intracellular domain cannot transduce 
biological signals independently. It was considered that they may act as a co-
receptor for VEGFR-1 and VEGFR-2. The interaction of ligand and receptor 
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could be enhanced and the signal might be amplified by their anticipation in the 
complex [123].  
Studies have shown that anti-angiogenesis therapy inhibits pancreatic 
tumor growth in mouse model. Currently targeting VEGF signaling and function is 
still a hot spot in anti-angiogenesis, tumor growth and metastasis. Strategies 
have been developed, including the use of anti-VEGF antibodies, targeting VEGF 
receptors to directly interfere the signal effect [124, 125]. Additionally, multiple 
genes, identified in pancreatic cancer switch of the "angiogenic network" [126, 
127], were also proposed to be the anti-angiogenic targets and targeted in 
experimental mouse model [58, 128]. These reported results from different 
experimental and clinical processes with different approaches showed 
the importance of the angiogenic process in pancreatic cancer. Also, replication 
deficient recombinant adenovirus mediated vasostatin was evaluated in human 
pancreatic cancer mouse model and shown to be efficient gene therapy for 
pancreatic carcinoma [129]. 
How the angiogenic molecules regulate angiogenesis process in pancreatic 
cancer is still not clear, while it is crucial to understanding the mechanism for 
designing effective anti-angiogenic therapies. Several reports including ours 
indicated that Sp1 plays a key role in VEGF and angiogenesis regulation of 
human pancreatic cancer [61, 130].  
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Figure 1 VEGF family members and their receptors VEGF family has 6 members, 
VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E (Virus protein, not shown here) and 
PIGF. VEGF has 5 receptors, VEGFR-1, VEGFR-2, VEGFR-3, Neuropilin-1 and 
Neuropilin-2. 
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SPECIFICITY PROTEIN 1 (Sp1) AND PANCREATIC CANCER 
Sp1 is a transcription factor that has three tandem zinc finger domains in its 
carboxyl terminal. It was the first sequence-specific regulator of mammalian gene 
transcription and was cloned by James Kadonaga in 1987 [131]. It can binds to 
Sp1 sites in the early promoter of SV40 virus with the carboxyl terminal 
characteristic tandem Cys2His2 ((Tyr, Phe)-Xaa-Cys-Xaa2,4-Cys-Xaa3-Phe-Xaa5-
Leu-Xaa2-His-Xaa3-5-His) zinc finger structure. It is believed that Sp1 can bind to 
GC and GT boxes (Sp1 site) in promoter and regulates the transcription. Sp1 
sites were found in numerous mammalian gene promoters. Sp1 was thought to 
be responsible for recruitment of TATA-binding protein (TBP) and to fix the 
transcription starting site and was considered as a basal transcription factor.  
Researchers have cloned transcription factors similar to Sp1 named as Sp2, Sp3, 
Sp4, Sp5, Sp6, Sp7 and Sp8 [132]. These eight molecules form the Sp multi-gen 
family. They all have the characteristic three tandem zinc finger structure at 
carboxyl terminal (Figure 2). Sp2, Sp3, and Sp4 also have glutamine-rich trans-
activation domain. But Sp2 is mainly expressed in neural system. Sp3 and Sp4 
are considered to be closely related to Sp1. The tandem zinc finger structure 
character is also appeared in Krüppel-like factor family. These transcription 
factors may have the transcriptional activation or repression function. 
Sp1 has been considered to be a basal factor since it was discovered. But more 
and more experimental evidence indicated that it can regulate a variety of 
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biologic functions. In cancer biology, these functions are important to tumor 
development and progression [60, 108, 109, 132-134]. Recently, several studies 
have reported that other Sp family members are also over-expressed in 
pancreatic cancer cells. The elevated expression of these molecules was also 
found in tumors compared with non-tumor tissue. These alterations play 
important role in the pancreatic cancer malignance nature.  
Pancreatic cancer is believed to be resulting from the genetic alternation of lots 
of genes. The average of the alternation was reported to be 63 [135]. All these 
alternations finally converge their signaling to a small number of transcription 
factors. Sp1 is considered to be one of the several oncogenic transcription 
factors and is important in pancreatic cancer pathogenesis [58, 132]. 
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Figure 2 Sp family members and their structures The Sp box (SPLALLAATCSR/KI) 
at the N-terminus is highly conserved of the Sp proteins. It contains an endoproteolytic 
cleavage site that is close to a proteasome-dependent degradation target region of Sp1 
in vitro. The (Btd) Buttonhead element is important in the synergistic activation by Sp 
protein with sterol-regulatory element-binding proteins. The carboxyl-terminal has the 
family marker region, featuring three Cys2His2 zinc “fingers”, which are required for 
sequence-specific DNA binding to GC-rich promoter elements. The (S/T) 
serine/threonine-rich subregions located next to the glutamine-rich regions are believed 
to be involved in post-translational modification. The (Q-rich) glutamine-rich portions of A 
and B are required for trans-activation. Each of which can stimulate transcription when 
tethered to DNA through a DNA-binding domain.  
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MATERIAL AND METHODS 
Information of Human Tissue Specimens and Patient  
Specimens of human pancreatic cancer tissue from the Pancreatic Cancer 
Tissue Bank (Shanghai Jiaotong University-Affiliated Ruijin Hospital) were used. 
These specimens were well archived. Pancreatic tumors in these patients were 
all primary pancreas tumors. Patients were diagnosed and treated at Ruijin 
hospital from 2002 to 2004. All of the patients did not received pre-operative 
chemotherapy or radiation therapy before surgery. 35 patients were selected to 
represent all stages of pancreatic tumor. The group of studied patients consisted 
of 20 men (57.1%) and 15 women (42.9%). 16 patients (45.7%) were aged > 60 
years, and 19 patients (54.3%) were aged < 60 years (mean age, 60.4 years). 
The tumor, lymph node, metastasis (TNM) criteria was used to staging the 
patients. There are 4 patients (11.4%) had stage I disease, 26 patients (74.3%) 
had stage II disease, 3 patients (8.6%) had stage III disease, and 2 patients 
(5.7%) had stage IV disease.  
Human Normal and Tumor Tissue Specimens Immunohistochemical 
Staining 
Sections (5 µm thick) of formalin-fixed, paraffin-embedded pancreatic tumor 
specimens were prepared and processed for immunohistochemistry to detect 
Sp1 and VEGF protein expression and tumor MVD by using anti-Sp1, anti-VEGF, 
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and anti-CD34 antibodies respectively. Antigen retrieval was performed with 
0.05% saponin for 30 min at room temperature. Endogenous peroxidase was 
blocked using 3% hydrogen peroxide in PBS for 12 min. The specimens were 
incubated for 20 min at room temperature with a protein blocking solution 
consisting of PBS (pH 7.5) containing 5% normal donkey serum and bovine 
serum albumin and then incubated at 4°C in polyclonal antibody against human 
Sp1 (clone PEP2) or VEGF overnight. The samples were then rinsed and 
incubated for 1 hour at room temperature with peroxidase conjugated anti-rabbit 
IgG. Next, the slides were rinsed with PBS and incubated for 5 min with 
diaminobenzidine. The sections were washed three times with distilled water, 
counterstained with Mayer’s hematoxylin (Richard Allan Scientific, Kalamazoo, 
MI), and washed once with distilled water and PBS. Afterward, the slides were 
mounted using Universal Mount (Biomeda Corporation, Foster City, CA) and 
examined using a bright-field Leica microscope.  
A positive reaction was indicated by a reddish-brown precipitate. Depending on 
the percentage of positive cells and staining intensity, staining was classified into 
three groups: negative, weak positive and strong positive. Specifically, the 
percentage of positive cells was divided into five grades (percentage scores) : 
<10% (1), 10–25% (2), 25–50% (3), 50–75% (4), and >75% (5). The intensity of 
staining was divided into four grades (intensity scores): no staining (1), light 
brown (2), brown(3), and dark brown (4). Sp1 and VEGF staining positivity were 
determined by the formula: overall scores = percentage score x intensity score. 
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The tissues sections were scored by 2 independent investigators prior knowing 
the patient outcomes, and the mean values of 2 independent scores are 
presented [60, 130, 136]. 
Cell Lines Information and the Corresponding Culture Conditions 
The human pancreatic adenocarcinoma cell lines AsPC-1, BxPC-3, and PANC-1 
were purchased from the American Type Culture Collection (Manassas, VA). FG 
human pancreatic adenocarcinoma cells were established by Vezeridis et al 
[137]. All of the cell lines were maintained in plastic flasks as adherent monolayer 
in minimum essential medium supplemented with 10% fetal bovine serum, 
sodium pyruvate, nonessential amino acids, L-glutamine, and a vitamin solution 
(Flow Laboratories, Rockville, MD). Human umbilical vein endothelial cells 
(HUVECs) were purchased from BD Biosciences (San Jose, CA) and were 
cultured with the endothelial cell culture medium (BD Biosciences, San Jose, CA) 
according to the manufacturer’s instructions. 
Small-interfering RNA Information 
Small interfering RNA (siRNA) reagents, including transfection reagents, were 
obtained from Invitrogen (Carlsbad, CA). A Sp1 Stealth RNAi duplex oligo was 
used to knock down Sp1 expression in pancreatic cancer cells. Non-targeting 
scrambled Stealth RNAi Negative Control siRNA were used as negative controls 
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according to the manufacturer's instructions. In vitro transfection was performed 
by using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA). 
Animals Information and Animal Care 
Female athymic nude mice and C57BL/6 mice were purchased from Jackson 
Laboratory (Bar Harbor, ME). The mice were housed in laminar flow cabinets 
under specific pathogen-free conditions and were used when they were 8 weeks 
old. The animals were maintained in facilities approved by the Association for 
Assessment and Accreditation of Laboratory Animal Care in accordance with the 
current regulations and standards of the U.S. Department of Agriculture, 
Department of Health and Human Services, and National Institutes of Health in M 
D Anderson Cancer Center animal facility. 
Animal Models of Tumor Growth and Metastasis 
Tumor cells (1 × 106 cells per mouse) were injected into the subcutis or pancreas 
of nude mice in groups of 5 to 10 mice. The animals were killed 60 days after the 
tumor-cell injection or when they had become moribund. Next, their primary 
pancreatic tumors were harvested and weighed. In addition, the liver from each 
mouse was removed and fixed in Bouin solution (BBC Biochemical, Dallas, TX) 
for 24 hours to differentiate the neoplastic lesions from the organ parenchyma; 
metastases on the surface of the liver were counted under a dissecting 
microscope. 
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Western Blot Protocol 
Whole-cell lysates of human pancreatic cancer cell lines or tissues were 
prepared [61]. Standard Western blot analyses were performed by using 
corresponding antibodies and the anti-rabbit immunoglobulin G (IgG) antibody, a 
horseradish peroxidase–linked F(ab')2 fragment obtained from donkey 
(Amersham, Arlington Heights, IL) as probing molecule. Equal protein-sample 
loading was monitored by probing the same membrane filters with an anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody [61]. The probe 
proteins were detected by using the Amersham enhanced chemi-luminescence 
system according to the manufacturer's instructions. 
Immunohistochemical Staining of Human Pancreatic Tumor Xenograft 
Specimens 
For VEGF and Sp1 staining of human pancreatic xenograft specimens, sections 
(5 µm thick) from formalin-fixed, paraffin-embedded pancreatic tumor specimen 
were de-paraffinized in xylene and rehydrated in graded alcohol. For CD31 
staining, frozen sections (6 µm thick) of tumor specimens were fixed with acetone. 
Sp1 and VEGF expression and MVD status in the sections were assessed as 
described previously. 
Matrigel Plug Assay 
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Matrigel (200 µl) containing 2 × 106 cells of different treated pancreatic cancer 
cells described above was injected subcutaneously into nude mice (2 injection 
sites per mouse). The Matrigel plugs were recovered from the mice 10 days after 
injection and carefully stripped of host tissues [138-142]. After photography, the 
Matrigel plugs were weighed and homogenized in 1 ml of distilled water and then 
centrifuged at 10,000 revolutions per minute for 5 minutes. The supernatants 
were collected for hemoglobin measurement using Drabkin solution (Sigma-
Aldrich, Saint Louis, CA) and measured with a Spectra Max M5 Microplate 
Manager enzyme-linked immunosorbent assay reader at 540 nm according to 
the manufacturer's instructions. The relative hemoglobin concentrations were 
calculated and further normalized according to the weights of the plugs. 
Endothelial Cell Tube Formation Assay 
A standard tube formation assay was performed using human umbilical vein 
endothelial cells (HUVECs) [138, 141]. PANC-1 cells (3 × 106) of deferent 
treatments were cultured in 1 ml of serum-free medium for 24 hours, and the 
medium was collected and centrifuged to remove any cell debris before its use 
as a conditional medium. HUVECs were cultured with endothelial cell culture 
medium (BD Biosciences, San Jose, CA). 24-well plates were coated with 
reconstituted Matrigel (BD Biosciences, San Jose, CA) following the 
manufacturer’s directions. 2 x 104 HUVECs were transferred to each well of 24-
well plates and incubated in culture medium at 37°C, 5% CO2 for adhesion. Then 
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culture medium was replaced with the conditional medium harvested from 
different treated cells and incubated for 18 hours [143]. The degree of tube 
formation was assessed as the percentage of cell surface area versus total 
surface area. Pictures were captured with bright-field Leica microscopy using a 
Spot-RT digital camera equipped with a Spot Imaging 4.7 program. 
Statistical Analysis 
For studies using human specimens, the chi-square test was performed to 
determine the significance of the differences between the covariates (Sp1, VEGF, 
and MVD). For in vitro and in vivo studies, each experiment was performed 
independently at least twice with similar results; 1 representative experiment is 
presented. The significance of the in vitro data was determined using the Student 
t test (two-tailed), whereas the significance of the in vivo data was determined by 
using the Mann-Whitney U test. P < 0.05 was deemed significant. 
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RESULTS 
Correlation of Sp1 expression levels with VEGF expression and MVD in 
human pancreatic cancer patients specimen 
Researchers have reported the importance of Sp1 in pancreatic cancer and that 
the expression of VEGF, one of the most key angiogenic molecules, depends on 
Sp1, which have suggested the role of angiogenesis in pancreatic cancer. But 
studies have not yet investigated the relation between MVD status, one of the 
angiogenic index, VEGF expression and Sp1 expression. The underlying 
interaction between these 3 factors in pancreatic cancer is not clear. 
To answer this important question, 35 primary pancreatic cancer tissue 
specimens were used to evaluate Sp1, VEGF expression and MVD status using 
immunohistochemistry staining and corresponding statistics. It was found that the 
MVD status was correlated highly with Sp1 expression (P < 0.001) (Fig. 3A1). 
The level of Sp1 expression was correlated significantly with VEGF expression 
level (P < 0.05) (Fig. 3A2).  
These co-relationships were confirmed by analyzing the consecutive sections of 
human pancreatic cancer specimens. The representative immunohistochemistry 
staining pictures of two representative patients’ specimens (selected from those 
35 patients) were shown in Figure 4.  The patient that has strong Sp1 expression 
(Fig. 4A1) has high MVD (Fig. 4A2), while the patient that has very weak Sp1 
expression (Fig. 4B1) has low MVD and very small micro vessel (Fig. 4B2).  
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Obviously the pattern of Sp1 expression was consistent with MVD status. 
Therefore, it can be concluded that Sp1 can regulate human pancreatic cancer 
angiogenesis with the supportiveness of these clinical evidence shown in Figure 
3 and Figure 4. 
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Figure 3 the level of transcription factor Sp1 expression correlates with the 
microvessel density (MVD) status in human pancreatic cancer. (A) Tissue sections 
were prepared from formalin-fixed, paraffin-embedded pancreatic tumors (35 patients). 
Immunohistochemical staining was performed by using specific antibodies against Sp1, 
vascular endothelial growth factor (VEGF), and CD34 (MVD) and was scored as 
described in Material and Methods. The direct correlations between Sp1 expression and 
MVD status (A1) (P < 0.001) and between Sp1 expression and VEGF expression (A2) (P 
< 0.05) were analyzed using the Person chi-square test.  
  
  
Figure 4 Representative 
consecutive tissue sections that were positive (
also were stained for CD34 expression (
shown (original magnification, ×100). It is noteworthy that Sp1 expression correlated 
directly with MVD status. 
 
immunohistochemistry staining results. 
A1) and negative (B1) for Sp1 expression 
A2, B2). Representative photomicrographs are 
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Two sets of 
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Sp1 expression were specifically knockdown in human pancreatic cancer 
cells  
Several pancreatic cancer cell lines, including AsPC-1, BxPC3, FG and PANC-1 
were transfected with Sp1 small-interfering RNA (si-Sp1) or control siRNA 
duplexes (si-Ctr) using Lipofectamine 2000 according the direction from 
Invitrogen (Carlsbad, CA). Cells were harvested after 24 hours of treatment to 
prepare whole cell lysates. Western blot was used to analyze protein level 
changes.   
Sp1 expression down-regulation was confirmed in these cells (Fig. 5A). Sp1 
protein was knockdown to less than 10% and even near 0% in particular cell line 
like PANC-1. In Sp1 protein family, Sp3 and Sp4 are close to Sp1. The specificity 
of Sp1 knockdown but not Sp3 or Sp4 was confirmed with Western Blot and the 
quantitative result was shown (Fig. 5B).  
The specificity of Sp1 knockdown in different species was also determined with 
tumor cell lines from human and mouse. Mouse melanoma cell line B16 and 
pancreatic tumor cell line H7 were selected. The specificity was confirmed with 
Western Blot (Fig. 6A). The siRNA targeting sequence is also listed and there is 
only one nuclear acid unmatched with mouse sequence (Fig. 6B). But the mouse 
Sp1 protein level has no change in comparison with human Sp1. 
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Figure 5 Knockdown of transcription factor Sp1 expression. For Sp1 knockdown, 
AsPC-1, BxPC-3, FG, and PANC-1 cells were transfected with Sp1 small-interfering 
RNA (si-Sp1) or with control small-interfering RNA (si-Ctr). Sp1 expression in these cells 
was confirmed by using Western blot analysis (A). PBS indicates phosphate-buffered 
saline; NS, nonspecific bands. The specificity of Sp1 knockdown in Sp protein of these 
cells was confirmed by using Western blot analysis and was quantitated (B). 
32 
 
 
 
 
Figure 6 Specificity of knockdown of transcription factor Sp1 expression. Human 
pancreatic cell line PANC-1, mouse melanoma cell line B16 and pancreatic cell line H7 
were transfected with Sp1 small-interfering RNA (si-Sp1) or with control small-interfering 
RNA (si-Ctr). Sp1 expression in these cells was confirmed by using Western blot 
analysis (A). PBS indicates phosphate-buffered saline; NS, nonspecific bands. The 
siRNA target sequence and the corresponding regions of human and mouse were 
shown (B). The only unmatched nuclear acid was marked in red.    
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Human pancreatic cancer cells lost the angiogenic potential after Sp1 
expression were knockdown 
To determine the Sp1 function in pancreatic cancer angiogenesis, tube-formation 
and Matrigel plug assay were performed as described in Material and Methods.  
Briefly, PANC-1 cells were transfected with control, si-Ctr or si-Sp1. The 
angiogenic potential of the supernatants of PANC-1 cells was determined using 
an endothelial cell tube formation assay following the protocol provided by 
supplier. The degree of tube formation was assessed as the percentage of cell 
surface area versus the total surface area and the statistic result was shown (Fig. 
7A). Representative photomicrographs of different treatment groups were taken 
in situ for tube formation of HUVECs incubated in the supernatants of different 
treatment groups (Fig. 7B). As it shown that PANC-1 cells transfected with si-Sp1 
reduced the capacity of its supernatant’s stimulate tube formation of endothelial 
cells when comparing with the capacity of supernatants of PANC-1 cells 
transfected with si-Ctr.  
The expression of several genes was analyzed after Sp1 knockdown with 
Western Blot (Fig. 8A). As it revealed that the expression of EGFR, PDGF, and 
VEGF were down regulated. These are consistent with other researchers’ 
reports. Sp1 sites in the promoter region of these angiogenic growth factors are 
the key regions to regulate their mRNA synthesis. 
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To further determine Sp1 knockdown effect on pancreatic cancer cell 
angiogenesis, Matrigel plug assay was performed according to Material and 
Methods. The angiogenic potential of pancreatic cancer cells was impaired in 
vivo (Fig. 8B). The data suggested that the knockdown Sp1 protein expression 
impaired the angiogenic potential of pancreatic cancer cells.  
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Figure 7 Human pancreatic cancer cells lost the angiogenic potential after 
knockdown of transcription factor Sp1 expression in vitro. The angiogenic potential 
of the supernatants of PANC-1 cells, PANC-1 cells transfected with si-Ctr, and PANC-1 
cells transfected with si-Sp1 was determined by using an endothelial cell tube formation 
assay (A). Representative photomicrographs were taken in situ of human umbilical vein 
endothelial cell tube formations in the supernatants of PANC-1 cells treated with si-Ctr or 
si-Sp1 (B). * P < 0.05 in a comparison between the treated and respective control 
groups. 
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Figure 8 Knockdown of transcription factor Sp1 expression attenuates human 
pancreatic cancer cell angiogenic potential in vivo and gene expression analyses 
in vitro. PANC-1 cells were treated as described above, and total protein lysates were 
prepared. Western blot was used to analyze vascular endothelial growth factor (VEGF), 
epidermal growth factor receptor (EGFR), and platelet-derived growth factor (PDGF) 
protein by using corresponding specific antibodies (A). For Matrigel plug assay, Matrigel 
(500 µL) that contained 2 × 106 PANC-1 cells or PANC-1 cells treated with si-Ctr or si-
Sp1 was used as described in Materials and Methods (B) (Hb indicates hemoglobin). It 
is noteworthy that the down-regulation of Sp1 expression impaired the angiogenic 
potential of pancreatic cancer cells in vitro and in vivo. * P < 0.05 in a comparison 
between the treated and respective control groups.  
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Knockdown of Sp1 expression suppressed human pancreatic cancer cells 
growth in vivo and correlated with impaired angiogenesis 
To determine whether cell cycle was affected after knockdown Sp1 expression in 
vitro, MTT assay and FACs analysis were performed as described in Material 
and Methods. 
Briefly, BxPC-3, FG, and PANC-1 cells were incubated in medium alone or in 
medium that contained Lipofectamine with si-Ctr or si-Sp1 for 3 days. 3-(4, 5-
dimethiazol-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay was 
used to assess the cell growth (Fig. 9A1). The viable cells that can be stained by 
trypan blue were counted (Fig. 9A2). The level of cell cycle progression was 
determined by using fluorescence-activated cell sorter analysis with propidium 
iodide staining (Fig. 9B). It was observed that the difference of S + G2 + M phase 
cells was about 2 percent. Knockdown Sp1 protein expression had minimal effect 
on tumor cell growth in vitro.  
Whether knockdown of Sp1 expression affects tumor growth in vivo was then 
determined. FG or PANC-1 cells transfected with si-Ctr or si-Sp1 were injected 
into the pancreas of mice. Mock transfected cells were also used as control. 10 
mice were used for each treatment group. Mice were sacrificed at the end of 
second month after the injection. Tumors were harvested and weighted for 
extended analysis. 
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When assessed by tumor weight, it was found that FG or PANC-1 cells 
transfected with si-Ctr produced larger tumors. But the cells transfected with si-
Sp1 produced smaller tumors (Fig. 10A). The MVD status of xenograft tumor 
tissue specimens was processed and photomicrographed as described in 
Material and Methods. Representative pictures of each treatment group from 
PANC-1 xerograph tumor were shown (Fig. 10B). It is clearly showed that, 
PANC-1 cells transfected with si-Sp1 formed tumors had less vascular than 
those formed by cells transfected with si-Ctr or mock transfection.  
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Figure 9 Knockdown of transcription factor Sp1 expression does not affect the in 
vitro growth of human pancreatic cancer cells. (A) BxPC-3, FG, and PANC-1 cells 
were treated for 3 days as described in the legend to Figure 4, and viable cells were 
determined using an 3-(4,5-dimethiazol-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide 
(MTT) assay (A1). PANC-1 cells were treated for 1 to 5 days as described in the legend 
to Figure 5, and viable cells were determined by viable cell counting (A2) PBS indicates 
phosphate-buffered saline; si-Ctr, control small-interfering RNA; si-Sp1, Sp1 small-
interfering RNA. (B) PANC-1 cells were treated with PBS (B1), si-Ctr (B2), or si-Sp1 (B3) 
for 48 hours as described in the legend to Figure 4. Cells were stained with propidium 
iodide and were subjected to fluorescence-activated cell sorter analysis. Percentages in 
M1 (G1), M2 (G2/M), M3 (S), and M4 (apoptosis) are calculated. This was 1 
representative experiment of 2 that produced similar results. 
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Figure 10 Knockdown of transcription factor Sp1 expression effectively attenuates 
the in vivo angiogenic potential and growth of human pancreatic cancer. FG or 
PANC-1 cells, FG or PANC-1 cells transfected with control small-interfering RNA (si-Ctr), 
and FG or PANC-1 cells transfected with Sp1 small-interfering RNA (si-Sp1) were 
injected into the pancreas of mice (n = 5). (A) Primary pancreatic tumors were weighed 
(A1, A2) PBS indicates phosphate-buffered saline. (B) The microvessel density status of 
PANC-1 pancreatic tumors formed by PANC-1 cells (B1), PANC-1 cells transfected with 
si-Ctr (B2), and PANC-1 cells transfected with si-Sp1 (B3) was determined by using 
CD31 staining. * P < 0.05 in a comparison between the treated and respective control 
groups. 
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To summarize the results, Sp1 expression correlated with VEGF expression and 
MVD in pancreatic tumor patient specimen. Sp1 protein can be knocked down 
specifically by using Sp1 specific siRNA oligo. Knockdown Sp1 expression in 
human pancreatic cancer cells leads to their losing of angiogenic potential. All 
the experimental results indicated that Sp1 has a key function in pancreatic 
cancer angiogenesis. 
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DISSCUSSION 
In this chapter, evidence from clinic and experiment were provided to show that 
transcription factor Sp1 is an important regulator of human pancreatic cancer 
angiogenesis. Especially, the Sp1 protein expression level was correlated directly 
with VEGF expression level and MVD status in human pancreatic cancer. 
Specifically knockdown human Sp1 expression led to the inhibition of pancreatic 
cancer angiogenesis and tumor growth in vivo. In addition, the anti-angiogenic 
activity of knock down Sp1 directly resulted in the down-regulation of Sp1 
downstream pro-angiogenic molecules VEGF, PDGF, and EGFR. The 
experimental results provided strong and important evidence to support the point 
that Sp1 is the key angiogenic regulator in human pancreatic cancer and would 
have significant implications in pushing the understanding of pancreatic cancer 
angiogenesis and important directional logical designing of effective anti-
angiogenesis therapies for the disease. 
As it has been discussed previously, angiogenesis has important role in both the 
maintaining of growth and metastasis pancreatic cancer. Both scientific 
researchers and clinicians have more and more interest in pancreatic cancer 
angiogenesis. The anti-angiogenic therapy is becoming a hot field and more 
scientific research results were translated to pre-clinic and clinic processes. 
Studies have demonstrated that anti-angiogenic therapies suppress tumor 
growth in pancreatic cancer mouse models [130, 144-147]. It has becoming 
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wildly recognized that human pancreatic cancer has elevated angiogenesis in 
which a distorted local balance of multiple pro-angiogenic and anti-angiogenic 
factors is involved [58, 84, 86, 87, 148, 149]. The imbalance is the predomination 
of angiogenic factors over angiogenic inhibitors. Among the growing list of 
angiogenic factors, all of the VEGF isoforms were reported to be important for 
the pancreatic tumor growth and metastasis [58, 84]. Additionally, other 
angiogenic factors are also over expressed in pancreatic cancer cells, such as 
EGF, HGF, TGFα, PDGF, FGFs (FGF-1, FGF-2, and FGF-5) and platelet-derived 
endothelial cell growth factor. The K-ras mutations and over-expression of HIF-
1α, thrombospondin-1, thymidine phosphorylase, and cathepsins B and L [58, 84] 
are also important contributing factors. Studies have demonstrated that 
expression of these factors or the combination of these factors or the 
combinations of them with other factors correlated with elevated vascular 
formation. The poor prognosis of pancreatic cancer patients under these 
pathological situations was also reported [58, 84]. Interference of the expression 
and the substance function of these factors have significant influences on 
angiogenesis and xenograft pancreatic tumor growth in mouse models [124, 150]. 
However simultaneously manipulating several target molecules remains a big 
challenge in clinic. 
It has been demonstrated that Sp1 is constitutive activated in pancreatic cancer 
cells. The constitutive Sp1 activity is essential for constitutive, inducible VEGF 
expression [58, 61, 88, 108, 134, 151]. The current experimental results 
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demonstrated that over-expression of Sp1 is correlated with MVD status in 
human pancreatic cancer tissue. Knockdown Sp1 protein expression with the 
siRNA oligo significantly inhibits the tumor angiogenic potential. The Sp1 
expression knocking down produced anti-angiogenic effect. That is consistent 
with down-regulated expression of several angiogenic signaling molecules by 
knockdown Sp1 expression. These molecules are in the signaling pathways that 
can regulate pancreatic cancer angiogenesis [60, 108, 109]. All these 
experimental results suggested that the transcriptional regulation is the 
underlying mechanism of over-expression of various angiogenic factors that 
collectively regulate pancreatic cancer angiogenesis [58, 88, 150]. 
The current study had also demonstrated that knockdown of Sp1 expression 
significantly reduced the angiogenic potential of human pancreatic cancer cells in 
vitro and led to the angiogenic phenotypic change in vivo. All of the evidence 
indicates that Sp1 plays an important role in pancreatic cancer angiogenesis 
regulation. 
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CHAPTER II 
Mithramycin Based Anti-angiogenic Therapy of Pancreatic 
Cancer in Mouse Model 
INTRODUCTION 
HUMAN PANCREATIC CANCER THERAPEUTICS  
In the past twenty to thirty years, pancreatic cancer patients’ cases have 
increased greatly. It is ranked as the fourth leading cause of cancer related death 
in the North America currently. Pancreatic cancer has a high case: fatality ratio 
and the etiology are still poorly explored although various approaches have been 
used to identify its origin [152]. Pancreas cancer patient is almost incurable. The 
overall survival (OS) rate is less than 4% [153]. If the tumor is detected in 
resectable localization and period, it has highly curable ratio. However, 
pancreatic cancer patients found in the stage are less than 20%. Recently 
medical imaging technology, such as positron emission tomographic (PET) scans, 
magnetic resonance imaging (MRI) scans, high resolution endoscopic ultrasound 
examination, and spiral computed tomographic (CT) scans has been improved. 
Together with the improving prevention, the pancreatic cancer diagnosis has 
been moving forward.  
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Besides the remaining problem of its diagnosis, pancreatic cancer is highly 
resistant to chemotherapy and radiation therapy. Surgery resection is still the 
primary choice when it is feasible [154-156]. There has been conflicting results 
reported by different researches on postoperative therapy. The management of 
patients after surgery remains to be another important question to be answered 
[157-159]. 
Currently, it is urgent to identify new targets for treating pancreatic cancer 
patients effectively. To fulfill the task, it is important to understand pancreatic 
cancer development and progression. There are average sixty three genetic 
alternations in pancreatic cancer patient. All of these genes that regulate 
angiogenesis, growth, and metastasis could be the potential targets [84, 85, 155-
157, 160-162]. Vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor (bFGF) and platelet-derived growth factor (PDGF) were considered to be 
the most important angiogenic factors. In pancreatic cancer epidermal growth 
factor (EGF) and its receptor (EGFR), insulin-like growth factor I (IGF-I) and its 
receptor, hepatocyte growth factor and its receptor Met were also considered to 
be important to angiogenesis [58, 84, 163]. Pancreatic cancer angiogenesis is 
correlated with these of angiogenic factors’ expression. Over-expression of 
VEGF has been reported to be correlated with microvessel density (MVD) in 
human pancreatic cancer. In mouse model VEGF-targeting therapy inhibited 
angiogenesis and tumor growth of pancreatic cancer [58, 84, 163]. But how these 
angiogenic factors could be up-regulated is to be determined [58, 84].  
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Not only our lab but also other group reported that VEGF expression was 
regulated by Sp1 in pancreatic cancer [61, 130, 151]. With the importance of 
VEGF in angiogenesis of pancreatic cancer, Sp1 could be an anti-angiogenic 
target in the treatment. Besides this, the role of Sp1 in anti-angiogenic 
therapeutic treatments is also to be determined. Detailed mechanism studies of 
these treatments would provide better understanding to the clinical outcomes.  
Pancreatic cancer treatment regimen might be developed systematically and 
specifically.  
MITHRAMYCIN 
Mithramycin is an aureolic acid antibiotic that is produced by a genus of bacteria 
Streptomyces sp [164, 165]. Most of the commercial available mithramycin is 
purified from Streptomyces argillaceus. In the past, it was mainly used to treat 
hypercalcemia, the high calcium level in blood or urine, in patients with bone 
metastases [166, 167]. Physicians also used it in treatment of Paget disease, 
testicular carcinoma and leukemia [168-173]. Recently, it was reported that 
mithramycin might be a potential neuroprotective drug in Huntington’s disease 
treatment [174].  
Mithramycin is believed to bind to GC-rich regions in DNA and thus regulates the 
transcription of the downstream genes [175]. Mechanistically two mithramycin 
molecules bind to DNA sequence with GC-base specificity. The binding is 
coordinated by a divalent cation, such as magnesium or zinc ion, and is believed 
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to be a reversible process [176]. Recently, it was reported that mithramycin 
stimulated tumor necrosis factor-alpha-related apoptosis-inducing ligand, Fas 
ligand and tumor necrosis factor induced apoptosis in tumor cells and prevented 
p53-mediated transcriptional activation [177-180]. The major mechanism of 
mithramycin, including anti-tumor activity, is believed to inhibit Sp1 binding 
activity. 
BEVACIZUMAB 
Living cells constantly need oxygen and nutrients to maintain the metabolism. 
More blood supply is needed by tumor cells comparing with normal cells for 
maintaining their higher proliferation rate [84, 181, 182]. During the tumor growth, 
tumor cells produce growth factors to activate angiogenesis process to trigger the 
formation of new blood vessels from the existing vessel. There are lots of growth 
factors that were demonstrated to activate this progress. Vascular endothelial 
growth factor (VEGF) was believed to be one of the most potent molecules for 
the growth of pancreatic tumor [116, 117]. Besides this, it was also demonstrated 
that VEGF promotes microvessel formation around tumor [116]. Moreover, it can 
also increase the blood vessel permeability to provide more nutrients for tumor 
cells growth and metastasis [117].  
Bevacizumab (Avastin™) was developed and marketed by Genentech. It is 
believed that Bevacizumab neutralizes soluble VEGF to inhibit new blood vessel 
formation and causes the destruction of the existing vessels [89, 183]. Thus the 
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blood supply to tumor cells would be blocked and tumor cells growth would slow 
down. Bevacizumab was approved by U.S. Food and Drug Administration (FDA) 
in 2004. It is the first approved biological therapy drug for combination 
chemotherapy in several types of tumors. Under the instruction of National 
Institutes of Health, Genentech cooperated with the National Cancer Institute 
(NCI) to develop of clinical practice of Bevacizumab in cancer treatment. 
Bevacizumab is humanized murine monoclonal antibody that binds to and 
inhibits VEGF [89]. A monoclonal antibody is a targeting protein produced by 
hybridoma.  
Use Sp1 as a potential anti-angiogenic target for effective targeting therapy in 
pancreatic cancer and its role in anti-angiogenic drug currently in clinic trial have 
not been explored till then. In this chapter, I sought to determine whether 
mithramycin has any effect on pancreatic cancer angiogenesis and if so, what 
the corresponding molecular mechanism is. 
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MATERIAL AND METHODS 
Chemicals and Reagents Information  
Mithramycin (1 mg per vial crystal powder) was purchased from Sigma Chemical 
Co (St. Louis, MO). It was dissolved in sterile water and diluted for actual use. 
Bevacizumab (25 mg/ml) was purchased from Genentech, Inc. For animal 
experiments, mithramycin (0.1–0.4 mg/kg body weight) and Bevacizumab (25–
100 µg per mouse) were given by i.p. injection twice a week or as indicated 
otherwise.  
Animals Information and Animal Care 
Female athymic BALB/c nude mice were purchased from The Jackson 
Laboratory. The mice were housed in laminar flow cabinets under specific 
pathogen-free conditions and used when they were 8 weeks old. The animals 
were maintained in M D Anderson Cancer Center animal facility approved by the 
Association for Assessment and Accreditation of Laboratory Animal Care in 
accordance with the current regulations and standards of the U.S. Department of 
Agriculture, U.S. Department of Health and Human Services, and NIH.  
Cell Lines and Culture Conditions Information 
The human pancreatic adenocarcinoma cell lines PANC-1 and BxPC3 were 
purchased from the American Type Culture Collection (Manassas, VA). FG 
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human pancreatic adenocarcinoma cells were established by Vezeridis et al 
[137]. The cell lines were maintained in plastic flasks as adherent monolayers in 
MEM supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential 
amino acids, L-glutamine, and a vitamin solution (Flow Laboratories).  
Immunohistochemical Analysis and Tumor MVD Quantification Protocols 
For CD31 staining, frozen tissue sections (5 µm thick) were fixed in acetone. 
Endogenous peroxidase in the specimens was blocked using 3% hydrogen 
peroxide in PBS for 12 min. The specimens were incubated for 20 min at room 
temperature in a protein-blocking solution consisting of PBS (pH, 7.5) containing 
5% normal horse serum and 1% normal goat serum and then incubated overnight 
at 4°C in a 1:100 dilution of monoclonal goat  anti-CD31 (PECAM1-M20), 
polyclonal rabbit anti-Sp1, or polyclonal rabbit anti-VEGF antibodies (Santa Cruz 
Biotechnology). The specimens were then rinsed and incubated with peroxidase-
conjugated anti-goat or anti-rabbit IgG for 1 hour at room temperature. Next, 
slides were rinsed with PBS and incubated with diaminobenzidine (Research 
Genetics) for 5 min. Frozen sections of the specimens were then washed twice 
with distilled water, counterstained with Mayer's hematoxylin (Biogenex 
Laboratories), and washed once each with distilled water and PBS. Sections 
were mounted on the slides using Universal Mount (Research Genetics), and the 
slides were examined under a bright-field microscope. A CD31-positive, Sp1-
positive reaction was indicated by a reddish-brown precipitate in the cytoplasm or 
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nuclei, respectively. For quantification of tumor MVD, vessels on each section 
were counted in five high-power fields (magnification, x200 [x20 objective and 
x10 ocular]) as described previously [184].  
Western Blot Analysis Protocol 
Whole-cell lysates were prepared from human pancreatic cancer cell lines and 
tissues [174]. Standard Western blotting was done using polyclonal rabbit 
antibodies against human and mouse Sp1, VEGF, PDGF and EGFR (Santa Cruz 
Biotechnology) and the anti-rabbit immunoglobulin G (IgG) antibody, a 
horseradish peroxidase–linked F(ab')2 fragment obtained from a donkey 
(Amersham). Equal protein-sample loading was monitored by probing the same 
membrane filter with antibodies against anti–β-actin or glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) [60]. The probe proteins were detected 
using the Amersham enhanced chemo-luminescence system according to the 
manufacturer's instructions.  
Sp1 Promoter Constructs Information and Analysis of Sp1 Promoter 
Activity with Luciferase Assay 
The minimal Sp1 promoter reporters in pGL3 luciferase constructs were 
generated and used as described previously [59, 61]. In order to examine the 
transcriptional regulation of the Sp1 promoters by Bevacizumab and mithramycin, 
PANC-1 cells were seeded to about 80% confluence in six-well plates (in 
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triplicate) and transiently transfected with 0.6 µg of minimum Sp1 reporter 
plasmids and 0.3 µg of effectors expression plasmids as indicated in each 
experiment using Lipofectamine (Invitrogen) according to the manufacturer's 
instructions. The reporter luciferase activity was measured 48 hours later using a 
luciferase assay kit (Promega). Promoter activity was normalized according to the 
protein concentration as described previously [59].  
Chromatin Immunoprecipitation Protocol 
Chromatin was prepared from cells and tumors as described previously [59]. 
Chromatin immunoprecipitation (ChIP) assay was done using the Chromatin 
Immunoprecipitation Assay Kit (Upstate Cell Signaling Solutions) according to the 
manufacturer's instructions. Briefly, DNA cross-binding proteins were cross-linked 
with DNA and lysed in SDS lysis buffer. The lysate was sonicated to shear DNA 
to 200 to 500 bp. After pre-clearing with a salmon sperm DNA/protein A agarose–
50% slurry for 30 min at 4°C, chromatin samples were immunoprecipitate d 
overnight with no antibody or an anti-Sp1 antibody (PEP2). The region between –
224 and –53 bp of the Sp1 promoter was amplified using the following primers: 
sense, 5'-caggcacgcaacttagtc-3', and antisense, 5'-gtaaggaggagggagcag-3'. PCR 
products were separated on a 1.5% agarose gel, stained with ethidium bromide, 
and visualized under UV light.  
Statistical analysis  
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Each experiment was done independently at least twice with similar results; one 
representative experiment is presented. The significance of the in vitro data was 
determined using Student's t test (two-tailed), whereas the significance of the in 
vivo data was determined using the two-tailed Mann-Whitney U test. For the in 
vivo experiments, the overall survival duration was calculated using the Kaplan-
Meier method. The log-rank test was used to compare the survival duration 
between groups. P < 0.05 was deemed significant. 
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RESULTS 
PART 1. MITHRAMYCIN TREATMENT ON HUMAN PANCREATIC CANCER 
ANGIOGENESIS 
Mithramycin treatment inhibits human pancreatic tumor growth in 
xenograft mouse models 
As it was introduced, mithramycin, as a Sp1 inhibitor, can inhibit Sp1 protein 
expression and interpose Sp1 recruitment to Sp1 sites. But whether it can inhibit 
pancreatic tumor growth in vivo is still unknown. 
First, a set of dose-response experiments was performed. BxPC-3 cells were 
injected subcutaneously into nude mice. When the tumors reached 4 mm in 
diameter, animals were given mithramycin in different doses (0.1, 0.2, and 0.4 
mg/kg) via intraperitoneal injection twice weekly. PBS was injected into a group 
of animals that used as controls. It was observed that treatment with mithramycin 
produced dose-dependent antitumor activity (Fig. 11).  
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Figure 11 Dose-dependent antitumor effects of mithramycin in xenograft models 
of human pancreatic cancer. BxPC3 cells were injected into the subcutis of nude mice 
(n = 5). When tumors reached around 4 mm in diameter, the animals received different 
doses of mithramycin [0.10 (M-10), 0.20 (M-20), and 0.40 (M-40) mg/kg] via i.p. injection 
twice a week. Tumors were measured once every week, and at each measurement, the 
mean ± SD tumor volume in the five mice in each group was calculated. The control 
mice and mice that received mithramycin were weighed at the time of experiment 
termination. Columns, mean weights; bars, SD. * P < 0.01 in a comparison between the 
treated and respective control groups 
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Then I sought to determine whether different administer and slow release of 
mithramycin would have the same effect on xenograft tumors. BxPC3 cells were 
inoculated to mice subcutis. When the tumors reached 4 mm in diameter, the 
animals were gave different doses of mithramycin (0.12 mg/kg, 0.25 mg/kg, and 
0.50 mg/kg) by subcutaneous or intraperitoneal injection twice weekly. It was 
observed that mithramycin treatment by intraperitoneal and subcutaneous 
administration can both produce dose-dependent antitumor activity (Fig. 12A). 
Next, similar experiments were performed using orthotopic mouse models. 
Pancreatic xenograft tumors were formed in mice pancreas as described in 
Material and Methods. Same dose and frequency of mithramycin were 
administered. It was found that treatment with mithramycin (0.25 mg/kg by 
intraperitoneal and subcutaneous administration) significantly inhibited the 
growth of BxPC-3, FG, and PANC-1 formed tumors (Fig. 12B).  
Furthermore, a histopathology examination was performed using pancreatic 
tumor specimens that were obtained from control mice and from mice that 
received low doses of mithramycin, because no tumors formed in mice that 
received high doses of mithramycin. Significant inhibition of Sp1 expression in 
tumor specimens from mice that received mithramycin compared with the control 
mice was observed (Fig. 12C), which was consistent with reduced MVD (Fig. 
12D).  
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Figure 12 Suppression of human pancreatic cancer growth by mithramycin in 
xenograft models (A) BxPC-3 cells were injected into the subcutis of groups of mice (n 
= 5 each). When tumors reached approximately 4 mm in greatest dimension, animals 
received injections of PBS or mithramycin (0.12 mg/kg, 0.25 mg/kg, and 0.50 mg/kg) 
subcutaneously (s.c.) or intraperitoneally (i.p.) twice weekly. The tumors were measured 
once weekly; and, at each measurement, the mean ± standard deviation tumor volume 
was calculated in each group of mice. (B) BxPC-3, FG, and PANC-1 cells were injected 
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into the pancreas of mice (n = 5). Two weeks after tumor injection (when tumors 
measured approximately 4 mm in greatest dimension), mice received i.p. or s.c. 
injections of mithramycin (0.25 mg/kg) twice weekly. PBS injection was used as a 
control. The resulting primary pancreatic tumors were weighed 45 days after the 
injection. (C) Sp1 expression was determined in PANC-1 tumor tissues collected from 
mice that received treatments with PBS (C1), mithramycin i.p. (C2), or mithramycin s.c. 
(C3) using immunohistochemistry. (D) Microvessel density status was assessed in 
PANC-1 tumor tissues collected from mice that received treatment with PBS (D1), 
mithramycin i.p. (D2), or mithramycin s.c. (D3) by using CD34 staining. This was 1 
representative experiment of 2 that produced similar results. * P < 0.05 in a comparison 
between the treated and respective control groups. 
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Gene expression analysis of mithramycin treated tumors  
Because mithramycin treatment produced dose-dependent tumor growth 
inhibition effect, I then sought to determine which potential angiogenic molecules 
were also affected in addition to Sp1, which were related to the anti-angiogenic 
effect.  
Western blot analysis was performed using total protein lysates extracted from 
the PANC-1 tumor tissue specimens that collected from mice that received 
treatment with PBS or mithramycin. Mithramycin suppressed the expression of 
Sp1 and its downstream molecules VEGF, EGFR, and PDGF (Fig. 13A), which 
was consistent with reduced MVD. It is noteworthy that the expression of Sp1 in 
normal tissues, including the liver, was not suppressed significantly (Fig. 13B). 
The results of this part suggested that mithramycin preferentially inhibits Sp1 
expression in growing tumors and has potent anti-pancreatic cancer activity. It 
was demonstrated that treatment with mithramycin inhibits Sp1 expression and 
down-regulates the downstream targets that are key to the angiogenesis of 
human pancreatic cancer as the consequence.  
  
 Figure 13 Preferential inhibition of transcription factor Sp1 expression in growing 
pancreatic tumors and anti
approximately 4 mm in greatest dimension, the animals received 2 subcutaneous (s.c.) 
injections of phosphate-buffered saline (PBS) (controls) or 
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the livers of untreated mice (control). (A) Western blot analysis was used to determine 
the expression of Sp1, vascular endothelial growth factor (V
factor receptor (EGFR), and platelet
growing in mice that had received 2 injections of PBS or 
intraperitoneally (mithramycin
3-phosphate dehydrogenase. (B) The levels of Sp1 expression were determined in both 
tumors and normal tissues by using Western blot analysis. 
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PART 2. ROLE OF SP1 IN CURRENT ANTI-ANGIOGENIC THERAPY IN 
PANCREATIC CANCER  
Bevacizumab and mithramycin combination produced synergistic 
antitumor effects in human pancreatic cancer mouse models  
Several researches have reported that Sp1 is the key for VEGF expression. 
VEGF plays an important role in regulating pancreatic cancer angiogenesis. 
However, whether Sp1 signaling was altered and what role that Sp1 has in anti-
VEGF anti-angiogenic therapy is unknown.  
To address these questions, the anti-tumor effect of anti-VEGF monoclonal 
antibody Bevacizumab was tested. Specifically, a dose-response experiment was 
first performed. BxPC3 cells were injected into subcutis of nude mice. When the 
resulting tumors reached 4 mm in greatest dimension, Bevacizumab (25, 50, and 
100 µg; Fig. 14) was given to the animals via i.p. injection twice a week. PBS was 
injected to a group of animals as controls. It was found that treatment with 
Bevacizumab produced dose-dependent antitumor activity. The mice that 
received Bevacizumab did not have significant body weight lose (Fig. 14). The 
experimental result suggested that Bevacizumab did not have any systemic side 
effects at the doses given. 
  
 
 Figure 14 Dose-dependent antitumor effects of 
of human pancreatic cancer.
(n = 5). When tumors reached around 4 mm in diameter, the animals received different 
doses of Bevacizumab [25 (
a week. Tumors were meas
± SD tumor volume in the five mice in each group was calculated.
mice that received were weighed at the time of experiment termination. 
weights; bars, SD. * P < 0.01
control groups.  
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Next, I sought to determine the treatment effect of the combination of the 
Bevacizumab and mithramycin at the dose that has minor anti-tumor effect. 
Experiments were performed using both BxPC3 and PANC-1 tumor cell models. 
Specifically, PBS, Bevacizumab (25 µg), mithramycin (0.10 mg/kg), or B + M 
were given to a group of nude mice. Consistent with last experimental result, 
administration of Bevacizumab or mithramycin alone produced minor antitumor 
activity. In contrast, administration of B + M produced synergistic antitumor 
activity without any observed systemic side effects (Fig. 15). Also, the mice body 
weights that received B + M is similar to the control mice that received PBS. 
Therefore, the use of B + M produced higher antitumor activity than the use of 
Bevacizumab or mithramycin alone did and no increased toxicity observed. 
These experimental results suggested that B + M treatment has a significant 
therapeutic benefit in pancreatic cancer mouse model.  
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Figure 15 Synergistic antitumor effects of treatment with Bevacizumab and 
mithramycin in xenograft models of human pancreatic cancer. Both (A) BxPC3 and 
(B) PANC-1 cells were injected into the subcutis of groups of mice (n = 5). Specifically, 
animals received injections of PBS (controls), Bevacizumab (25 µg), mithramycin A (0.10 
mg/kg), or B + M. Tumors were measured once every week, and at each measurement, 
the mean ± SD tumor volume in the five mice in each group was calculated. A and B, * P 
< 0.01 in a comparison between the treated and respective control groups. C, 
representative tumor sizes in each group of BxPC3 model mice. 
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Bevacizumab and mithramycin produced prolonged survival in orthotopic 
xenograft model of human pancreatic cancer  
PANC-1 cells were injected into the pancreas of nude mice and then treatments 
were given to them as described in Figure 15. Animal survival was monitored 
daily. The experiment was terminated at 160 days after tumor-cell injection. It 
was found that Bevacizumab or mithramycin alone treatment produced a slightly 
increased survival duration comparing with PBS group. However, the B + M 
combination treatment produced longer survival duration when comparing with 
the other three groups of mice and the difference was statistically significant (Fig. 
16A). In addition to this, the decreased incidence of tumor growth in the pancreas 
and of metastasis in the liver and/or other organs was found in the B + M 
combination treatment group (Fig. 16B). The decrease is statistically significant. 
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Figure 16 Prolonged survivals of mice that received treatment with Bevacizumab 
and mithramycin in xenograft models of human pancreatic cancer. PANC-1 cells 
were injected into the pancreas of nude mice (17–20 mice per group). The mice received 
treatment as described in Fig. 15. The entire experiment was terminated 120 days after 
tumor-cell injection. A, animal survival was monitored daily until the termination of the 
experiment. Cum, cumulative. B, tumor growth in the pancreas and metastasis in the 
liver and/or other organs were evaluated and expressed as the incidence (%). * P < 0.01 
in a comparison between the treated and respective control groups.  
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Bevacizumab treatment up-regulates Sp1 and VEGF expression and its 
reversal by treatment with mithramycin 
In this experiment, genes expression analysis was used to determine the 
mechanism of the synergistic effect of B + M combination treatment.  
Specifically, PANC-1 tumor tissues were harvested from mice that received 
treatment with PBS, Bevacizumab, mithramycin, or B + M. The tissue specimen 
were then stained using specific antibodies against Sp1, VEGF and CD31 
respectively. Representative pictures from each group were shown in Figure 17. 
As it shows, Bevacizumab treatment increases Sp1 and its downstream molecule 
VEGF expression. However, treatment with mithramycin suppressed Sp1 and 
VEGF expression, which was consistent with reduced MVD (Fig. 17 and 18 A), 
whereas treatment with Bevacizumab at the low dose alone did not significantly 
reduce MVD, which was consistent with increased Sp1 expression. 
Next western blot analysis was performed. Tumor tissue specimens were 
collected from mice that received treatment with PBS, Bevacizumab, 
mithramycin, or B + M. Total protein lysates were extracted and run western blot 
analysis As shown in Fig. 18B and C. Consistent with the immunohistochemistry 
staining results, the expression of Sp1 and its downstream angiogenic factor 
VEGF were up-regulated by Bevacizumab treatment.  
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Figure 17 Gene expression analyses of tumor from mice that received treatment 
with Bevacizumab and mithramycin in xenograft models of human pancreatic 
cancer. Sp1, VEGF expression were determined in PANC-1 tumor tissues collected 
from mice that received treatments in the experiment described in Figure 15 using 
immunohistochemistry. MVD status was assessed by using CD31 staining.   
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Figure 18 Analysis of MVD and gene expression of tumor from mice that received 
treatment with Bevacizumab and mithramycin in xenograft models of human 
pancreatic cancer. The tumor tissues described in Fig. 15 were collected and 
processed as described in Materials and Methods. A, MVD was quantitated according to 
CD31 staining. B, total protein lysates were harvested from tumor tissues and the level 
of protein expression in them was determined using Western blot analysis. Equal 
protein-sample loading was monitored by probing the same membrane filter with an 
anti–β-actin antibody. NS, nonspecific band. C, the levels of Sp1 and VEGF expression 
were quantitated and expressed as fold change. * P < 0.01 in a comparison between the 
treated and respective control groups. 
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Figure 19 Analysis of Sp1 and VEGF expression in tumor tissues. The tumor 
tissues described in Fig. 14 were collected and western blot analysis was done using 
specific antibodies against Sp1, VEGF, and β-actin.  
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These data indicated that the Bevacizumab neutralizes circulating VEGF and 
Sp1 expression may be up-regulated through the positive feedback loop, which 
may lead to increased VEGF expression in cell. However, because of the initially 
decreased VEGF neutralized by Bevacizumab, the MVD levels may be 
decreased for some degree. However, Sp1 up-regulation may also activate the 
other downstream angiogenic protein besides VEGF. The over-expression of 
these angiogenic proteins might trigger the tumor’s resistance to Bevacizumab 
treatment.  
As it was shown, low dose of Bevacizumab (25 µg) treatment that activates Sp1 
expression does not have significant antitumor activity. Expression level of Sp1 in 
tumors harvested from mice that received high dose of Bevacizumab (100 µg) 
treatment, which had a significant antitumor activity, was determined. The 
western blot result was shown in Fig. 19. Sp1 protein level was found to be 
decreased by the 100 µg of Bevacizumab treatment. However, Sp1 expression 
up-regulation by the 25 µg of Bevacizumab treatment was also observed. It was 
also found that the alteration of VEGF expression level was consistent with that 
of the Sp1 expression level. These data indicated that the ineffective low dose of 
Bevacizumab treatment could up-regulate Sp1 expression and might contributed 
to Bevacizumab resistance.  
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Bevacizumab and mithramycin treatment effect on the growth and gene 
expression in human pancreatic cancer cells 
Since Bevacizumab treatment could up-regulate Sp1 and its downstream 
angiogenic molecules in vivo, I then want to determine how that affect gene 
expression in pancreatic cancer cells in vitro. PANC-1 and BxPC3 cells were 
incubated in 100µg/ml of Bevacizumab in culture medium. Cells were harvested 
in 6, 12, 24 and 48 hours and cell number were counted in day 1 to 5. As it was 
shown in Figure 20, Bevacizumab treatment did not affect BxPC3 cells growth 
(Fig. 20A) or PANC-1 cells growth (Fig. 20B) in vitro. The western blot was 
shown in Fig. 20C. Neutralization of VEGF by Bevacizumab treatment did not 
affect the expression of Sp1 and its downstream molecules VEGF and EGFR. As 
it was reported previously that Bevacizumab primarily neutralizes the circulating 
VEGF to block its autocrine effect on tumor angiogenesis [124, 147-149, 185]. 
This was confirmed by the current experimental result. 
However, mithramycin treatment inhibits PANC-1 cells (Fig. 21A) growth in vitro 
in dose-dependent manner. The IC50s of 24 and 48 hours of mithramycin 
treatment were >1.5 µmol/L and 0.15 µmol/L respectively. But 0.05 and 0.10 
µmol/L of mithramycin treatment inhibited the expression of Sp1 and its 
downstream molecules EGFR and VEGF in PANC-1 cells (Fig. 21B). These data 
indicated that mithramycin treatment inhibited tumor cells growth and down-
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regulated Sp1 and its downstream molecules’ expression. Whereas 
Bevacizumab did not has the effect. 
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Figure 20 Effects of treatment with Bevacizumab on the growth of and gene 
expression in human pancreatic cancer cells in vitro. BxPC3 (A) and PANC-1 cells 
(B) were incubated for 1 to 5 d in medium alone or a medium containing 100 µg/ml 
Bevacizumab. The viable cells were counted every 24 h. C; PANC-1 cells were 
incubated for 6 to 48 h in medium alone or a medium containing 100 µg/ml 
Bevacizumab. Total protein lysates were harvested from the cell cultures, and the level 
of Sp1, EGFR, and VEGF protein expression was determined using Western blot 
analysis. Equal protein-sample loading was monitored by probing the same membrane 
filter with an anti-GAPDH antibody. 
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Figure 21 Effects of treatment with mithramycin on the growth of and gene 
expression in human pancreatic cancer cells in vitro. A and B, PANC-1 cells were 
treated with mithramycin at concentrations ranging from 0.1 to 1.2 µmol/L for 24 and 48 
h. A, cytotoxicity was assessed using the 3-(4,5-dimethylthiazol-2-thiazolyl)-2,5-
diphenyltetrazolium bromide assay. B, the level of gene expression was determined 
using Western blot analysis. NS, nonspecific.  
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Effects of Bevacizumab and mithramycin treatment on Sp1 recruitment into 
the Sp1 promoter in vitro and in vivo in human pancreatic cancer cells  
As it was shown previously, mithramycin treatment down-regulated Sp1 protein 
expression and B + M combination treatment produced significant anti-tumor 
effect. I then sought to determine the molecular mechanism. Luciferase assay 
was performed to determine Sp1 promoter activity. Briefly, Sp1 promoter reporter 
constructs were transfected into PANC-1 cells. The cells were then incubated in 
100µg/ml Bevacizumab or 0.1µmol/L mithramycin in culture medium. Mithramycin 
treatment suppressed Sp1 promoter activity significantly in vitro, but 
Bevacizumab treatment did not. However, Sp1 promoter activity suppression 
produced by mithramycin treatment was eliminated by further deletion of Sp1-
binding sites in its promoter (Fig. 22 A and B). 
Next ChIP assay was used to further determine the mechanism. Consistently, 
mithramycin treatment significantly reduced Sp1 protein recruiting onto its own 
promoter as shown in Figure 23 A, whereas Bevacizumab treatment (100µg/ml) 
did not produce this effect. Then tumors tissues harvested in the experiment 
described in Figure 15 were used to perform ChIP assay. Both mithramycin 
treatment and B + M treatment suppressed Sp1 protein recruitment to its own 
promoter (Fig. 23B). These data suggested that mithramycin treatment 
interposes Sp1 recruitment on its promoter and blocks Sp1 transcription to down-
regulate Sp1 and its downstream target molecules, such as VEGF. This might 
disrupt the positive feedback produced by Bevacizumab. 
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Figure 22 Effects of Bevacizumab and mithramycin treatment on Sp1 promoter 
activity in vitro. A, schematic structures of the minimal Sp1 promoters. The nucleotide 
positions and sequences of Sp1-binding sites and PCR forward and reverse primers 
flanking those sites for ChIP assay are shown. B, Sp1 promoter reporter constructs were 
transfected into PANC-1 cells in triplicate and incubated for 12 h. The cells were then 
incubated for another 24 h in medium alone or a medium containing 100 µg/ml 
Bevacizumab or 0.1 µmol/L mithramycin. Total protein lysates were harvested from the 
cell cultures for measurement of Sp1 promoter activity using a luciferase assay kit. The 
relative Sp1 promoter activities were assessed, and the activity in treated groups was 
expressed as the fold change of that in their respective control groups. 
 Figure 23 Effects of treatment with 
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In this part, it was found that treatment with ineffective low dose of Bevacizumab 
up-regulated Sp1 expression. This positive feedback is then positive regulate the 
expression of various angiogenic factors, including VEGF. Mithramycin treatment 
inhibited Sp1 expression and repressed VEGF expression and tumor 
angiogenesis. Low doses of B + M combination treatment produced a synergistic 
anti-angiogenic effect (super additive at least). This effect was correlated with 
Sp1suppression activity and Sp1 downstream target molecules down-regulation. 
These experimental findings suggested that Bevacizumab block VEGF signaling 
in vivo may triggers the positive feedback to up-regulate p1 expression. This 
feedback might leads to the up-regulation of multiple angiogenic factors including 
VEGF in turns. In this way, Bevacizumab treatment neutralizes VEGF and may 
lead to compensatory up-regulation pathways, such as transcription factor Sp1, 
which may lead to drug resistance as consequence. However, mithramycin 
treatment interfere Sp1 recruitment onto its promoter and inhibit Sp1 expression 
to block this feedback mechanism. For the first time, it was shown that Sp1 was 
regulated by itself and this auto-regulation can be interrupted by mithramycin. 
These findings provide a novel paradigm of synergism between anti-angiogenic 
and chemotherapeutic reagent. This might help physician in designing regimens 
that can improve anti-angiogenic activity and reverse resistance in anti-
angiogenic therapy. 
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DISSCUSSION 
In this chapter, it was demonstrated that mithramycin, a Sp1 inhibitor, has 
significant anti-pancreatic cancer capability. The experimental results indicated 
that mithramycin has strong anti-angiogenic capability with no systemic side 
effects observed at a given dose. Low dose of mithramycin treatment did not 
inhibit tumor angiogenesis significantly when comparing with high dose treatment. 
But low dose of mithramycin treatment did reduce Sp1 and its downstream 
angiogenic molecules’ expression the in tumors. The impact of mithramycin 
treatment on the expression of Sp1 in xenograft tumors and non-tumor tissues 
were evaluated. This is to determine the Sp1 inhibition ability of mithramycin on 
normal tissue at the given dose, which was then used to modify the responses 
and optimize its treatment strategy. Whether mithramycin preferentially affects 
neo-angiogenesis and tumor-associated stem cells is unknown and could be 
further investigated. Besides the anti-angiogenic effect, the mithramycin 
treatment may produce antitumor activity through a mechanism of induction of 
tumor cell apoptosis in vivo. These indicated that mithramycin may affect tumor 
cell survival by more than only one anti-angiogenic mechanism. As it was 
reported by other labs that mithramycin could sensitize of tumor cells to 
apoptosis induction through tumor necrosis factor-alpha-related apoptosis-
inducing ligand, Fas ligand and tumor necrosis factor [177, 179, 180]. 
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Lots of experimental results demonstrated that angiogenesis had important roles 
in maintained growth and metastasis of pancreatic cancer. Studies reported by 
different groups showed that pancreatic xenograft tumors in mouse model were 
suppressed by anti-angiogenic treatment [124, 126, 150]. Several strategies that 
target VEGF signaling and function have been designed and tested. Pancreatic 
cancer angiogenesis, growth, and metastasis were inhibited and survival was 
improved in nude mouse models. Anti-VEGF antibodies, VEGF antisense oligo-
nucleotides, VEGF-directed ribozymes and VEGF fused to a diphtheria toxin 
were all demonstrated to be effective. Also VEGF receptor interference was 
developed, such as dominant-negative flk-1, and the small molecules tyrosine 
kinase inhibitors targeting VEGF receptors [144, 146, 186, 187]. Even the specific 
cyclooxygenase-2 inhibitor celecoxib was shown to suppress pancreatic cancer 
growth and metastasis through inhibiting VEGF expression. The other anti-
oxidant isoflavone genistein was also reported to suppress angiogenesis through 
down-regulating VEGF [130, 188, 189]. It was also reported that the expression 
of VEGF correlates with MVD status and disease progression in different types of 
tumors [58, 84]. All the results from different clinical researches and experimental 
designs using different approaches indicated that angiogenesis is very 
importance in tumor biology. VEGF played a crucial role in tumor angiogenesis.  
In xenograft mouse models, it has been shown that targeting VEGF produced 
inhibited tumor growth, but the VEGF targeting reagent was reported to have 
limited response when used as mono-agent regimen in clinic studies [148, 190]. 
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Tumor cells need to be destroyed instead of to be kept static by therapeutic 
drugs to cure cancer. It has been shown that anti-angiogenic approaches 
produced more effective results when they were used together with 
chemotherapy and/or radiation therapy. In combination with other strategies 
VEGF targeting were reported to be more effective for neuroendocrine tumor, 
renal cell carcinoma, and some sarcomas [191-196]. Also, gemcitabine was 
reported to facilitate anti-angiogenic therapies when used together with anti-
VEGF, anti–VEGF receptor and anti-EGFR antibodies [185, 197-199]. Anti-
angiogenic therapies that target single molecule produced limited therapeutic 
effect suggested the importance of targeting several angiogenic signals and 
effectors factors at the same time [58]. Targeting these individual molecules 
might also potentially result in resistance to the targeting drug through feedback 
mechanisms.  
Recently Bevacizumab was used in combination with gemcitabine, capecitabine 
for advanced local-regional pancreatic cancer in randomized phase II and III 
clinical trials. It was also used as combination with rapamycin, everolimus, 
erlotinib or oxaliplatin in treatments of other type of cancer and produced 
promising results in clinical trials [200-202]. Mechanisms have been proposed for 
the synergy between anti-angiogenic therapy and chemotherapy. It was proposed 
that VEGF targeted therapeutics may stabilize mature blood vascular since 
VEGF was demonstrated to be a vascular permeability factor. Thus interstitial 
fluid pressure was decreased, which may in turn enhance chemotherapy reagent 
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delivery [203]. There is research even pointed out that pancreatic cancer 
treatment needs to enhance vasculature to achieve better chemotherapeutic 
results [204]. On the other hand, it was also proposed that Bevacizumab 
treatment may reverse apoptotic resistance mediated by neuropilin receptors 
[124, 205].  
Several other angiogenic growth factors, such as FGFs, EGF, HGF, transforming 
growth factor-α and platelet-derived growth factor were also reported to be over-
expressed in pancreatic cancer cells [58, 84]. It has been reported that the 
expression of these and many other factors correlate with increased vasculature 
and poor prognosis in pancreatic cancer patients [58, 84, 85]. Therefore, other 
factors are involved in the pancreatic cancer growth and metastasis process as 
well as VEGF. In autocrine and paracrine fashion, these factors produce 
angiogenic activity to promote pancreatic cancer cell growth and angiogenesis 
and enhance pancreatic tumor metastasis eventually [84, 85]. It was reported that 
angiogenesis and growth of pancreatic cancer could be interrupted by interfering 
the expression or function of the angiogenic factors discussed in mouse models. 
Such as dominant-negative IGF-IR (IGF/IGF-1R interferer) or NK4 (a competitive 
antagonist of HGF) treatment produced anti-angiogenic activity [58, 84]. It would 
be predicted that targeting these angiogenic factors at the same time would 
produce promising therapeutic effect. However, it has been a clinical challenge 
for multiple targeting at the same time.  
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Previous experimental results have indicated that a potential underlying 
mechanism for over-expression of various angiogenic factors exited. With this 
mechanism, angiogenesis was collectively regulated with the over-expression of 
the angiogenic factors as the directed result [58, 88]. Angiogenic signals carried 
by these angiogenic factors transduced through intra-cellular signal net work and 
converged to transcription factors. In pancreatic cancer one of the transcription 
factor Sp1 is reported to be constitutively over-expressed in vitro. The constitutive 
and inducible VEGF expression depends on the Sp1constitutive activity [58, 61, 
88, 108, 134]. It was also reported that over-expression of Sp1 is correlated with 
MVD in human gastric cancer specimen assessed by immunohistochemistry 
staining [58, 88]. In the present study mithramycin treatment was shown to 
interpose Sp1 recruitment onto its own promoter, which blocked Sp1 transcription 
and decreased Sp1 protein. This is correlated with the suppressed tumor 
angiogenesis and growth in vivo. All of these evidences indicate that Sp1 plays 
important roles in the regulation of angiogenesis and Sp1/VEGF signaling 
pathway is important in pancreatic cancer.  
Mithramycin treatment at the ineffective low dose did not produce significant 
antitumor activity in the present study. But in tumors the VEGF protein level was 
reduced when comparing with control group. This result indicated that 
mithramycin treatment at the given dose inhibits Sp1 and VEGF expression, but 
there are small amount of extracellular matrix–associated VEGF in the tumor bed 
or the circulating VEGF remaining. These two parts of VEGF residues may 
86 
 
initiate angiogenesis. The angiogenic phenotype may also be maintained by the 
small amount of VEGF leftover. It is critical, if that is the case, to remove the 
remaining VEGF to diminish the angiogenic signals. This might be the reason that 
why the given low dose of mithramycin treatment cannot produce significant 
antitumor activity. It was also observed that many Sp1 downstream angiogenic 
molecules, including VEGF, were up-regulated by low dose of Bevacizumab 
treatment. This might be the reason why treatment with Bevacizumab as single 
drug was not sufficient to produce sustained anti-angiogenesis. However, the 
combination of Bevacizumab and mithramycin can neutralize soluble and 
membrane bounded VEGF, block the feedback on Sp1 and its downstream 
angiogenic molecules and produce synergistic anti-angiogenic effect in 
pancreatic xenograft mouse models. All of these experimental results suggesting 
that Sp1 and Sp1/VEGF signaling are very important in pancreatic cancer 
angiogenesis.  
Collectively, the present experimental results suggest that VEGF targeting 
treatment, such as Bevacizumab, may trigger the drug resistance in pancreatic 
cancer. The positive feedback through activated Sp1 expression and Sp1 
downstream angiogenic molecules’ activation as the consequence might be one 
of the underlying mechanisms. The combination treatment of mithramycin and 
Bevacizumab can block Sp1 transcriptional regulation and neutralize VEGF, 
which is a novel strategy of targeting angiogenesis. The proposed molecular drug 
resistance formation model might be extended to other type of cancer 
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therapeutics besides pancreatic cancer and other type of therapy besides anti-
angiogenesis. The rationale represented by the combination use of Bevacizumab 
and mithramycin would push the pancreatic cancer anti-angiogenic therapy step 
forward. 
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CHAPTER III 
Synergistic Antitumor Regulation of Mithramycin and 
Tolfenamic acid of Pancreatic Cancer in Mouse Models 
INTRODUCTION  
ANTI-ANGIOGENIC THERAPY APPROACHES AND REATIONAL 
As it has been discussed previously, angiogenesis is an important process for 
tumor cell survival and metastasize to distant organs. It is dynamically regulated 
by lots of angiogenic factors and angiogenic inhibitors [66, 181].  Under the 
hypoxia condition in tumor micro-environment, angiogenic factors are over-
expressed and predominate over angiogenic inhibitors. These angiogenic factors 
whose over-expression leads to the imbalance are the targets of current anti-
angiogenic targeted therapies [66, 82, 86, 87, 206]. Among the growing list of 
angiogenic factors, VEGF is considered as one of the very important ones for 
most of the tumor types. 
Among current anti-VEGF target therapies, Bevacizumab is considered to be one 
of the most successful ones. Bevacizumab is the first FDA approved anti-
angiogenic medicine. It is a humanized murine monoclonal Antibody [207]. Its 
murine origin is A4.6.1. It recognizes VEGF121, 165 and 189 [208]. The in vivo 
embryonic chicken angiogenesis and vascular permeability assay showed it can 
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neutralize VEGF. In preclinical study, xenograft tumor growth was inhibited by 
Bevacizumab treatment [148, 183, 209-211]. Bevacizumab is now used in 
different phases for different types of cancer. It is now the 1st line medicine of 
colon cancer treatment.  
It is known that VEGF transcriptional control is also being used. The most 
important one is HIF-1α targeted therapy from each level. HIF-1α is monomer 
that can form heterodimeric transcription factor HIF. HIF-1β (or Arnt) is the other 
component. HIF can bind to hypoxia-response element (HRE, which contains the 
consensus core sequence 5’-R(A/G)CGTG-3’ ) and activates the transcription of 
VEGF and VEGFR1 [212]. HIF-1α is over-expressed in most types of solid 
tumors. Its expression might be activated by intra-tumoral hypoxia and genetic 
alterations, including oncogenic gain-of-function mutations and tumor-suppressor 
loss-of-function mutations, such as VHL (Von Hippel-Lindau) and PTEN. Under 
hypoxic condition, VEGF transcription is up-regulated by HIF heterodimer binding 
on the HRE in its promoter region. There is also an internal ribosomal entry site 
allowing preserved translation when facing normal cellular hypoxic shutdown. 
VEGF biological function is also influenced by hypoxia-inducible expression and 
post-transcriptional regulation of VEGF receptors. Mouse genetics study shows 
inactivation of HIF-1α resulting in abnormal vascular development and embryonic 
lethality. The HIF-1α-/- mice have angiogenic defects in both the yolk sac and the 
development of embryonic tissue [213]. 
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A variety of genetic and pharmacologic approaches have been used to target 
HIF-1α. As a transcription factor, its DNA binding affinity can be targeted; its 
protein stability can also be targeted since it has a natural stable/degraded 
regulation mechanism; its mRNA stability can also be targeted using siRNA(small 
interfering RNA) technology; its protein level may be targeted by regulating the 
translation process; the important PI3K/Akt signaling pathway is another aspect 
of HIF-1α targeting to affect its transcription; the nuclear translocation of HIF-1α 
and the dimerization process may be desirable targets for the inhibition of HIF-1 
activity [214]. 
As a receptor of VEGF signaling pathway, the most important angiogenesis 
signaling pathway, VEGFRs are certainly the hot targets of anti-angiogenic 
therapy. Although with questionable specificity, small molecule tyrosine kinase 
inhibitor (TKI) is always the hot spot of VEGFR targeting research. VEGFR can 
also be targeted by chimeric receptor and VEGF trap (soluble chimeric VEGFR). 
They can all inhibit tumor growth in vivo. Antisense oligonuleotides is also used 
to target VEGFR. Besides these, small molecule VEGFR-2 kinase and 
phosphorylation inhibitors are used. Neutralizing Antibodies directed against 
VEGFR such as DC101, IMC-1C11and CDP791 were also developed. 
USE OF MITHRAMYCIN IN SP1 MANIPULATION 
Mithramycin is an antibiotic that has antitumor activity as shown in the last 
chapter. It is produced by the bacteria of the genus Streptomyces sp and can 
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bind to Sp1 site in DNA sequence [164, 165]. Mithramycin can compete with 
transcription factor binding to promoters and block transcription activation. After 
binding on DNA, it forms a stoichiometry drug-mental complex through the 
chelation with divalent ion. This interaction is non-covalent and is reversible [168, 
175, 215]. It is believed that mithramycin selectively competing with Sp1 to 
regulate the transcription of genes that have Sp1 site(s) in their promoter region 
[175, 176, 216]. As it has been shown in last chapter, mithramycin treatment 
down-regulates Sp1 protein through blocking Sp1 transcriptional auto-regulation 
and decreases Sp1 downstream angiogenic molecules as a consequence. The 
major mechanism of mithramycin antitumor effect is believed to inhibit Sp1 
activity [217]. While this manipulation to Sp1 protein is the result of Sp1mRNA 
transcription blockage instead of working on the protein molecules directly.  
TOLFENAMIC ACID (TA) HAS ANTI-TUMOR ACTIVITY 
Tolfenamic acid is a prostaglandin as well as leukotriene synthesis inhibitor 
through blocking cyclooxygenase catalytic activity. It is a well-documented and 
effective non-steroidal anti-inflammatory drug for treatment of migraine symptom. 
It can relieve endometriosis symptoms in patients with pelvic endometriosis 
through inhibiting prostaglandin synthetase and antagonizing prostaglandins at 
the target level [218]. It is also used to diminish the local reactions after telecobalt 
therapy [219]. TA has a long history to be used in treating acute migraine attack 
either alone or with caffeine, metoclopramide and pyridoxine as adjuncts [220-
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222]. When TA was used together with sumatriptan, migraine recurrence 
decreased dramatically [223]. Recently, TA is reported to be an urokinase 
plasminogen activator inhibitors in a computational study by docking 
nutraceuticals to the 3D structure of urokinase [224]. It was also reported to 
activate Sp1, Sp3, and Sp4 protein degradation in pancreatic cancer cells and 
this was accompanied by decreased VEGF and VEGF receptor 1 in both mRNA 
and protein level [225, 226].  
In this chapter, the synergistic anti-tumor effect of mithramycin and TA 
combination and the corresponding anti-angiogenic, cell growth inhibition 
mechanism were investigated.  
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MATERIALS AND METHODS  
Chemicals and Reagents Information 
Mithramycin (1 mg/vial crystal powder) and TA were purchased from Sigma 
Chemical Co. (St. Louis, MO). Mithramycin was dissolved in sterile water 
diluted for actual use. TA was mixed with corn oil (Sigma Chemical Co., St. 
Louis, MO) to corresponding concentration. For animal experiments, 
mithramycin was administered by intraperitoneal injection twice a week or as 
indicated otherwise. TA was administered through oral gavage.  
Cell Lines and Culture Conditions Information 
The resources of human pancreatic adenocarcinoma cell lines PanC-1, FG and 
BxPC3 are the same as previous chapters. The cell lines were maintained in 
plastic flasks as adherent monolayers in minimal essential medium 
supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential 
amino acids, L-glutamine, and a vitamin solution (Flow Laboratories, Rockville, 
MD). 
Animals Information 
Female athymic BALB/c nude mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). The mice were housed in laminar flow cabinets 
under specific pathogen-free conditions and used when they were 8 weeks old. 
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The animals were maintained in facilities approved by the Association for 
Assessment and Accreditation of Laboratory Animal Care in accordance with 
current regulations and standards of the U.S. Department of Agriculture, U.S. 
Department of Health and Human Services, and National Institutes of Health in 
M D Anderson Cancer Center animal facility. 
Western Blot Analysis Protocol 
Whole-cell lysates were prepared from human pancreatic cancer cell lines or 
tissues [61]. Standard Western blotting was performed using polyclonal rabbit 
antibodies against human and mouse Sp1, VEGF (Santa Cruz Biotechnology, 
Santa Cruz, CA) and the anti-rabbit IgG antibody, a horseradish peroxidase-
linked F(ab')2 fragment obtained from a donkey (Amersham, Arlington Heights, 
IL). Equal protein-sample loading was monitored by probing the same 
membrane filter with antibodies against glyceraldehyde-3-phosphate 
dehydrogenase [227]. The probe proteins were detected using the Amersham 
enhanced chemiluminescence system according to the manufacturer’s 
instructions. 
Matrigel Plug Assay  
Matrigel (200µl) containing 2 × 106 cells were injected subcutaneously into nude 
mice (2 injection sites per mouse). The Matrigel plugs were recovered from the 
mice 10 days after injection and carefully stripped of host tissues. After 
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photomicrography, the Matrigel plugs were weighed and homogenized in 1 ml of 
distilled water and then centrifuged at 10,000 revolutions per minute for 5 
minutes. The supernatants were collected for hemoglobin measurement using 
Drabkin solution (Sigma Chemical Company, St. Louis, MO) and a Microplate 
Manager enzyme-linked immunosorbent assay reader at 540 nm according to 
the manufacturer’s instructions. The relative hemoglobin concentrations were 
calculated and further normalized according to the weights of the plugs. 
Immunohistochemical Analysis and Quantification of Tumor MVD 
For CD31 staining, frozen tissue sections (5µm thick) were fixed in acetone. 
Endogenous peroxidase in the specimens was blocked using 3% hydrogen 
peroxide in PBS for 12 minutes. The specimens were incubated for 20 minutes 
at room temperature in a protein-blocking solution consisting of PBS (pH 7.5) 
containing 5% normal horse serum and 1% normal goat serum and then 
incubated overnight at 4°C in a 1:100  dilution of monoclonal goat anti-CD31 
(PECAM1-M20), polyclonal rabbit anti-Sp1, polyclonal rabbit anti-VEGF or 
polyclonal rabbit anti-PCNA antibodies (Santa Cruz Biotechnology) [229]. The 
specimens were then rinsed and incubated with peroxidase-conjugated anti-
goat or anti-rabbit IgG for 1 hour at room temperature. Next, the slides were 
rinsed with PBS and incubated with diaminobenzidine (Research Genetics, 
Huntsville, AL) for 5 minutes. Frozen sections of the specimens were then 
washed three times with distilled water, counterstained with Mayer’s 
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hematoxylin (Biogenex Laboratories, San Ramon, CA), and washed once each 
with distilled water and PBS. The slides were mounted with Universal Mount 
(Research Genetics) and examined under a bright-field microscope. A positive 
reaction was indicated by a reddish-brown precipitate in the cytoplasm (CD31) 
or nuclei (Sp1). For quantification of tumor MVD, vessels on each section were 
counted in five high-power fields (magnification, x200 [x20 objective and x10 
ocular]) as described previously [230, 231]. 
Chromatin Immunoprecipitation Protocol 
Chromatin was prepared from cells and tumors as described previously [59]. 
Chromatin Immunoprecipitation (ChIP) assay was done using the Chromatin 
Immunoprecipitation Assay Kit (Upstate Cell Signaling Solutions) according to 
the manufacturer’s instructions. Briefly, DNA cross-binding proteins were cross-
linked with DNA and lysed in SDS lysis buffer. The lysate was sonicated to 
shear DNA to 200 to 1000 bp. After pre-clearing with a salmon sperm 
DNA/protein A agarose–50% slurry for 30 min at 4°C, chromatin samples were 
immunoprecipitated overnight with no antibody or an anti-Sp1 antibody (PEP2). 
The region between -224 and -53 bp of the Sp1 promoter was amplified using 
the following primers: sense, 5'-caggcacgcaacttagtc-3', and antisense, 5'-
gtaaggaggagggagcag-3'. The region between -272 and +18 bp of the VEGF 
promoter was amplified using the following primers: sense, 5'-
ccgcgggcgcgtgtctctgg-3', and antisense, 5'-tgccccaagcctccgcgatcctc-3'. PCR 
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products were separated on a 1.5% agarose gel, stained with ethidium bromide, 
and visualized under UV light. 
Statistical Analysis  
Each experiment was done independently at least twice with similar results; 
one representative experiment is presented. The significance of the in vitro data 
was determined using Student’s t test (two-tailed), whereas the significance of 
the in vivo data was determined using the two-tailed Mann-Whitney U test. For 
the in vivo experiments, the overall survival duration was calculated using the 
Kaplan-Meier method. The log-rank test was used to compare the survival 
duration between groups. P ≤ 0.05 was deemed significant. 
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RESULTS  
Effects of treatment with mithramycin and/or tolfenamic acid on the gene 
expression in human pancreatic cancer cells  
To determine the impacts of mithramycin and TA treatment on gene expression 
in pancreatic cancer cells, PANC-1 and BxPC3 cells were incubated in a medium 
alone or a medium containing mithramycin (0.01, 0.05 and 0.1 µmol/L) and/or TA 
(5, 10, 20 µmol/L). Western blot results showed that Sp1 protein level was down-
regulated by both mithramycin and TA treatment as single reagent in a dose-
dependent pattern after 24 hours of treatment (Fig. 24A and 24B) in vitro.  
As shown in Fig. 25, low dose of mithramycin and TA combination treatment can 
significantly down-regulate Sp1 protein level. These data suggested that high 
dose of mithramycin and TA treatment can decrease Sp1 protein level 
significantly at around 24 hours and low dose of mithramycin and TA combination 
produced synergistic down-regulation effect on Sp1 protein at around 12 hours. 
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Figure 24 Tolfenamic acid, mithramycin treatments down-regulate Sp1 in vitro 
PANC-1 cells were incubated in medium alone or a medium containing mithramycin or 
TA. Total protein lysates were harvested from the cell cultures, and the level of Sp1 and 
VEGF protein expression was determined using Western blot analysis. Equal protein-
sample loading was monitored by probing the same membrane filter with an anti- 
GAPDH antibody. A1, mithramycin (0.01, 0.05 and 0.1 µmol/L) were used to treat 
PANC-1 cells and samples were harvested at 24hours. A2, the quantitative results of 
Sp1 and VEGF in A1 normalized with GAPDH; Blank treatment was set as 100%. B1, 
TA (5, 10, 20 µmol/L) was used to treat PANC-1 cells and sample were harvested at 24 
hours. B2, the quantitative results of Sp1 and VEGF in B1 normalized with GAPDH; 
Blank treatment was set as 100%. 
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Figure 25 Tolfenamic acid/mithramycin treatments down-regulate Sp1 in vitro 
PANC-1 cells were incubated in medium alone or a medium containing mithramycin 
and/or TA. Total protein lysates were harvested from the cell cultures, and the level of 
Sp1 and VEGF protein expression was determined using Western blot analysis. Equal 
protein-sample loading was monitored by probing the same membrane filter with an anti- 
GAPDH antibody. A, Mithramycin (0.05 µmol/L) and TA (5 µmol/L) was used to treat 
PANC-1 cells and samples were harvested at 12 hours. B, the quantitative results of Sp1 
and VEGF in A normalized with GAPDH. Blank treatment was set as 100%. 
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Tolfenamic acid and mithramycin treatments down-regulate Sp1 protein 
through different mechanism  
As it was shown in last chapter, mithramycin down-regulates Sp1 expression 
through interfere its recruitment on its own promoter to block Sp1 mRNA 
transcription. To determine how TA treatment regulates Sp1 protein expression 
in pancreatic cancer cells, PANC-1 cells were incubated in a medium alone or a 
medium containing mithramycin (0.1 µmol/L) with or without lactacystin (2 
µmol/L) or TA (20 µmol/L) with or without lactacystin (2 µmol/L) for 24 hours. 
Lactacystin is a selective inhibitor of the proteasome. Cells that were treated with 
0.1% DMSO was set as control to TA treatment. Western blot results showed 
that Sp1 protein level was down-regulated by both mithramycin and TA treatment 
without lactacystin. However, when cells were treated with both TA and 
lactacystin, Sp1 protein level was not decreased. Thus, TA appears to activate 
proteasome-dependent Sp1 degradation, while mithramycin does not affect 
proteasome-dependent Sp1 degradation because the combination of 
mithramycin and lactacystin down-regulated Sp1 protein to the same level as 
mithramycin alone. This result shows that both mithramycin and TA down-
regulate Sp1 protein expression but through different mechanism. 
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Figure 26 Through different mechanism tolfenamic acid mithramycin treatments 
down-regulate Sp1 in vitro PANC-1 cells were incubated in medium alone or a 
medium containing DMSO (0.1%), mithramycin (0.1 µmol/L), TA (20 µmol/L) or 
lactacystin (2 µmol/L) as shown. Total protein lysates were harvested from the cell 
cultures, and the level of Sp1 protein expression was determined using Western blot 
analysis. Equal protein-sample loading was monitored by probing the same membrane 
filter with an anti- GAPDH antibody.  
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Synergistic cytotoxicity of mithramycin and tolfenamic acid in human 
pancreatic cell lines in vitro  
MTT assay was performed to determine the pancreatic cancer cell killing effect in 
vitro. FG and BxPC3 cells were treated with mithramycin (0.025, 0.05, 0.1, 0.2, 
0.4 µmol/L) and/or TA (2.5, 5, 10, 20, 40 µmol/L) for 24 to 48 hours. Figure 27 
shows the MTT results. Drug concentration was optimized to the extent in which 
there is no extensive cytotoxic effect by a single drug treatment. Under the 
condition, mithramycin and TA showed higher cell killing effect in combination 
treatment.  
To determine the type of mithramycin and TA treatment interaction effect, the 
MTT cell experimental data were subjected to further statistical analysis. Loewe 
additivity model, one of the general reference models for evaluating drug 
interactions, was used [232]. Based on this model, S-PLUS/R was used to 
evaluate mithramycin and TA interaction. Basically Chou and Talalay’s median 
effect equation was used to do the calculation [233]. FG (Fig 28) and BxPC3 (Fig 
29) analyses output were shown. Table 1 shows the estimated interaction indices 
from the corresponding fitted dose-effect curve (Fig. 28 A2 and B2) respectively. 
Table 2 shows the estimated interaction indices from the corresponding fitted 
dose-effect curve (Fig. 29 A2 and B2) respectively. The interaction was 
considered to be synergy if the interaction index is < 1, while was considered to 
be additivity when interaction index is equal to 1 [232]. When the standard 
104 
 
deviation is span 1, the interaction was also considered to be additivity for 
restriction analysis. All of the calculated interaction indexes were less than 1. But 
in Fig. 28, 4 of the 5 of 24 hours and all 48 hours data points and in Fig. 29, 3 of 
the 5 of 24 hours and all 48 hours data points that were considered to be synergy 
for restriction analysis. This experimental result indicated that the combination of 
mithramycin and TA produced synergistic cytotoxicity on FG and BxPC3 cells in 
vitro. 
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Figure 27 Mithramycin and tolfenamic acid treatment inhibit cell growth in vitro FG 
(A) and BxPC3 (B) cells were treated with mithramycin at concentrations ranging from 
0.025 to 0.4 µmol/L and TA from 2.5 to 40 µmol/L for 24 (A1, B1) and 48 hrs (A2, B2). 
Cytotoxicity was assessed using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide assay.  
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Figure 28 Synergistic cytotoxicity of mithramycin and tolfenamic acid in vitro in 
FG cell MTT assay data of FG cell in Figure 26 was analyzed with S-PLUS/R software 
using Chou and Talalay’s median effect equation. A, 24 hours data. B, 48 hours data. 
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Figure 29 Synergistic cytotoxicity of mithramycin and tolfenamic acid in vitro in 
BxPC3 cell MTT assay data of BxPC3 cell in Figure 26 was analyzed with S-PLUS/R 
software using Chou and Talalay’s median effect equation. A, 24 hours data. B, 48 hours 
data.  
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Table 1 Statistics of interaction of mithramycin and tolfenamic acid in the FG cell cytotoxicity 
experiment 
Time Point Interaction   Additivity Estimated 
 Value 
95% confidential 
interval 
Conclusion 
Mithramycin 
(nmol/L) 
TA 
(µmol/L) 
 
 
24 hours 
25 
50 
100 
200 
400 
2.5 
5 
20 
20 
40 
0.156 
0.156 
0.133 
0.188 
0.289 
[0.047, 0.515]  
[0.046, 0.531]  
[0.042, 0.558]  
[0.048, 0.740]  
[0.069, 1.205] 
Synergy  
Synergy  
Synergy  
Synergy 
Additivity 
 
 
48 hours 
25 
50 
100 
200 
400 
2.5 
5 
20 
20 
40 
0.0018 
0.0030 
0.0050 
0.0042 
0.0059 
[0.0008, 0.0043]  
[0.0013, 0.0071]  
[0.0020, 0.0122]  
[0.0014, 0.0128]  
[0.0018, 0.0198] 
Synergy  
Synergy  
Synergy  
Synergy  
Synergy  
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Table 2 Statistics of interaction of mithramycin and tolfenamic acid in the BxPC3 cell 
cytotoxicity experiment 
Time Point Interaction   Additivity Estimated 
 Value 
95% confidential 
interval 
Conclusion 
Mithramycin 
(nmol/L) 
TA 
(µmol/L) 
 
 
24 hours 
25 
50 
100 
200 
400 
2.5 
5 
20 
20 
40 
0.177 
0.127 
0.081 
0.300 
0.317 
[0.093, 1.090]  
[0.086, 1.043]  
[0.018, 0.377]  
[0.026, 0.615]  
[0.034, 0.921] 
Additivity 
Additivity  
Synergy  
Synergy  
Synergy 
 
 
 
48 hours 
25 
50 
100 
200 
400 
2.5 
5 
20 
20 
40 
0.0046 
0.0029 
0.0029 
0.0059 
0.0066 
[0.0014, 0.0150]  
[0.0008, 0.0111]  
[0.0007, 0.0118]  
[0.0014, 0.0243]  
[0.0015, 0.0291] 
Synergy  
Synergy  
Synergy  
Synergy  
Synergy  
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Effects of treatment with mithramycin and tolfenamic acid on Sp1 
recruitment into the Sp1 and VEGF promoter in vitro  
In the present experiments, I sought to determine whether treatment with 
tolfenamic acid and mithramycin regulated Sp1 expression at the transcriptional 
level. Luciferase assay was performed. Briefly, Sp1 and VEGF (Fig.30A) 
promoter reporter constructs were transfected into PANC-1 cells and then 
incubated the cells in 0.01 µmol/L mithramycin or 5 µmol/L tolfenamic acid in 
culture medium. In vitro, treatment with tolfenamic at did not suppress Sp1 and 
VEGF promoter activity much, whereas treatment with mithramycin has certain 
inhibition effect. However, the suppressing ability of mithramycin to Sp1 and 
VEGF promoter were eliminated by further deletion of Sp1-binding sites in the 
promoters. Furthermore, combination treatment of mithramycin and TA suppress 
VEGF (Fig. 30B) and Sp1 (Fig. 30C) promoter activity significantly.  
Next ChIP assay was performed as described in Material and Methods. The 
experimental results were consistent with Luciferase assay results. Mithramycin 
treatment reduced Sp1recruitment to its own and VEGF promoter as shown in 
Figure 31. While treatment with TA has minor affect on Sp1 recruitment to its 
own and VEGF promoter in vitro (Fig. 31). In contrast, treatment with 
mithramycin and TA combination suppressed Sp1 protein recruitment to its own 
promoter and VEGF promoter significantly. These data suggested that 
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mithramycin and TA combination treatment synergistic reduced Sp1 recruitment 
to its own and VEGF promoter. 
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Figure 30 Effects of tolfenamic acid and mithramycin treatment on Sp1 and VEGF 
promoter activity in vitro. A, schematic structures of the minimal VEGF promoters. The 
nucleotide positions and sequences of Sp1-binding sites and PCR forward and reverse 
primers flanking those sites for ChIP assay are shown. B, VEGF and C, Sp1 promoter 
reporter constructs were transfected into PANC-1 cells in triplicate and incubated for 12 
h. The cells were then incubated for another 24 h in medium alone or a medium 
containing 0.01µmol/L mithramycin or 5 µmol/L TA. Total protein lysates were harvested 
from the cell cultures for measurement of promoter activity using a luciferase assay kit. 
The relative promoter activities were assessed, and the activity in treated groups was 
expressed as the fold change of that in their respective control groups. * P < 0.05 in a 
comparison between the treated and respective control groups.  
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Figure 31 Effects of mithramycin and tolfenamic acid on Sp1 and VEGF promoter 
in vitro Chromatin Immunoprecipitation was performed as described in Materials and 
Methods.  Chromatin was extracted from PANC-1 cells that were incubated in vitro for 2 
d in medium alone or a medium containing 0.5 µmol/l mithramycin, 50 µmol/l TA, 0.5 
µmol/L mithramycin + 50 µmol/L TA (M+T). A specific anti-Sp1 antibody and 
oligonucleotides flanking the (A) Sp1, (B) VEGF promoter regions containing Sp1-
binding sites was used. Lane 1, input chromatin DNA; lane 2, chromatin DNA with 
control IgG; lane 3, chromatin DNA with anti-Sp1 antibody. 
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Anti-angiogenesis effects of mithramycin and tolfenamic acid in vitro  
Pancreatic cancer cell PANC-1 was treated with 50 µmol/L tolfenamic acid and/or 
0.1 µmol/L mithramycin. Western blot was used to determine Sp1 protein 
alternation in these cells. Sp1 expression down-regulation was confirmed. 
Endothelial cell tube formation assay was used to determine the angiogenic 
potential of the supernatants of PANC-1 culture. The degree of tube formation 
was assessed as the percentage of cell surface area versus the total surface 
area (Fig. 32A). Representative photomicrographs were taken in situ for tube 
formation of HUVECs incubated in the supernatants (Fig. 32B). Mithramycin 
and/or tolfenamic acid treatment reduced the capacity of supernatants of PANC-
1 cells to stimulate tube formation of endothelial cells compared with the capacity 
of supernatants of control PANC-1 cells. The impaired angiogenic potential was 
confirmed further by in vivo Matrigel plug assay (Fig. 32C) (protocol was 
described in Material and Methods). These data indicated that mithramycin 
and/or tolfenamic acid treatment reduced the angiogenic potential of PANC-1 
cells. 
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Figure 32  Mithramycin and tolfenamic acid treatment affect PANC-1 cell 
angiogenic phenotype A, Culture supernatants were harvested from PANC-1 cells 
treated with 0.5 µmol/L mithramycin, 50 µmol/L TA, 0.5µmol/L mithramycin + 50µmol/L 
TA respectively. The angiogenic potentials of the supernatants were determined by an 
endothelial cell tube formation assay. Representative pictures were taken in situ for tube 
formation in the supernatant of the above 4 groups. (B) The degree of tube formation 
was assessed as the percentage of cell surface area versus total surface area. Control 
cell cultures were given arbitrary percentage values of 100. C, For a Matrigel plug assay, 
Matrigel (200 µl) that contained 2×106 PANC-1 cells or PANC-1 cells treated with 0.5 
µmol/L mithramycin,  50 µmol/LTA or 0.5 µmol/L mithramycin + 50µmol/L TA was used 
as described in the text (see Materials and Methods). It is noteworthy that the down-
regulation of Sp1 expression impaired the angiogenic potential of pancreatic cancer cells 
in vitro and in vivo. * P < 0.05 in a comparison between the treated and respective 
control groups. 
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Antitumor effects of mithramycin and tolfenamic acid in human pancreatic 
cancer xenograft mouse models  
Both mithramycin and TA treatment can down-regulate Sp1, VEGF and VEGFR 
[225, 226]. However, it is unknown whether these two drugs interact 
synergistically in regulating Sp1 activity and tumor growth. To determine the two 
drugs’ function on tumor in vivo, PANC-1 xenograft tumor mouse model was 
used. Specifically, dose-response experiments were performed. The animals with 
PANC-1 xenograft tumor were given different doses of mithramycin (0.1, 0.4, and 
1.5 mg/kg; Fig. 33A) via intraperitoneal injection twice a week and TA (10, 40, 80 
mg/kg) via oral gavage three times a week. It was found that treatment with 
mithramycin and TA produced dose-dependent antitumor activity. But the mouse 
body weight, as a drug cytotoxicity index, also decreased in a dose-dependent 
manner (Fig. 33B). 
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Figure 33 Anti-tumor activity of mithramycin and tolfenamic acid treatment in vivo 
A-B, Dose-dependent antitumor effects of mithramycin and TA in xenograft models of 
human pancreatic cancer. A, PANC-1 cells were injected into the subcutis of nude mice 
(n = 5). When tumors reached around 4 mm in diameter, the animals received different 
doses of (A1) mithramycin (0.1, 0.4, 1.5mg/kg) via i.p. injection twice a week, (A2) TA 
(10, 40, 80 mg/kg) via oral gavage three times a week. Tumors were weighted at the 
time of experiment termination. (B) Mice bodies were also weighted at the same time. 
Columns, mean weights; bars, SD. * P < 0.05 in a comparison between the treated and 
respective control groups. 
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Next, an experiment using PANC-1 tumor cell mouse models in which PBS, 
mithramycin (0. 1mg/kg), TA (10mg/kg), or M+T were administered to a group of 
nude mice was performed. It was found that administration of TA or mithramycin 
alone produced minor antitumor activity. In contrast, administration of 
mithramycin and TA produced significant antitumor activity (Fig. 34A1 and 34A2). 
Furthermore, the use of low dose of TA and MIT produced synergistic antitumor 
activity without producing significant systemic side toxicity, as indicated by a lack 
of significant weight loss (Fig. 34B). Therefore, the use of low dose of TA and 
mithramycin produced significant antitumor activity without toxicity. This suggests 
that treatment with low dose of mithramycin and TA has a significant therapeutic 
benefit. 
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Figure 34 Synergistic anti-tumor activity of mithramycin and tolfenamic acid in 
vivo Parallel to Figure 33, a group of mice with PANC-1 tumor were treated with 
0.1mg/kg mithramycin and 10mg/kg TA. A1, All the 4 groups of mice tumors were 
measured once every week, and at each measurement, the mean ± SD tumor volume in 
the five mice in each group was calculated. Tumor weight (A2) and mice body weights 
(B) were measured at the end of the experiment. A3 and A4, Representative mouse and 
the tumor from each group. * P < 0.05 in a comparison between the treated and 
respective control groups. 
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Effects of mithramycin and tolfenamic acid treatment on gene expression 
and Sp1 recruitment on Sp1 and VEGF promoters in Vivo  
To determine the gene expression alternation with treatment of mithramycin and 
TA, immunohistochemistry staining was performed using the PANC-1 tumor 
tissue collected from mice that received treatment with PBS, TA, mithramycin, or 
T+M. As shown in Fig. 35, treatment with TA or mithramycin alone can decrease 
expression of Sp1 and its downstream molecule VEGF. Tumor microvessel 
density, shown with CD31 staining, also decreased comparing with control group. 
Whereas mithramycin and TA combination treatment suppressed Sp1 and VEGF 
expression dramatically, this was consistent with the much reduced MVD. 
Besides these, mithramycin and/or TA treatment decreased tumor PCNA protein 
level, especially in combination treatment. These data suggested that the 
synergy anti-tumor activity of mithramycin and TA combination may be produced 
through not only anti-angiogenesis effect, but also the direct growth inhibition of 
tumor cell proliferation. Indeed, there is also the synergy low-dose combination 
cytotoxicity, but no cytotoxicity when use alone, in vivo. 
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Figure 35 Analysis of gene expression and microvessel formation in tumor tissues 
The tumor tissues described in Fig. 33 were collected and processed to do 
immunohistochemistry staining of Sp1, VEGF, PCNA and micro-blood-vessel as 
described in Materials and Methods. 
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To confirm the Sp1 and VEGF alternation, western blot analysis was then 
performed. Total protein lysates extracted from the PANC-1 tumor tissue 
specimens collected from mice that received treatment with PBS, TA, 
mithramycin, or T+M were used. As shown in Fig. 36A, Sp1 and VEGF protein 
were down-regulated especially in the combination treatment. BxPC3 tumor 
tissue collected from mice that received the same treatment was also analyzed 
(Fig. 36 B).  
Then I sought to determine whether Sp1 transcription was regulated by TA and 
mithramycin treatment in vivo. Similar to in vitro, mithramycin treatment reduced 
Sp1recruitment onto its own and VEGF promoter as shown in the ChIP assay. 
While treatment with TA has minor affect on Sp1 recruitment to its own and 
VEGF promoter in vitro (Fig. 37). In contrast, treatment with mithramycin and TA 
suppressed Sp1 protein recruitment to its own promoter significantly.  
These data suggested that mithramycin and TA combination treatment 
synergistic down-regulates Sp1 and VEGF expression and produces tumor 
suppression effect in vivo. 
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Figure 36 Effects of treatment with mithramycin and tolfenamic acid on Sp1 
protein level The tumor tissues described in Fig. 34 were collected and processed as 
described in Materials and Methods. A-B, total protein lysates were harvested from 
tumor tissues and the level of protein expression in them was determined using Western 
blot analysis. Equal protein-sample loading was monitored by probing the same 
membrane filter with an anti–GAPDH antibody. A, PANC-1 xenograft tumors; B, BxPC3 
tumors.  
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Figure 37 Effects of mithramycin and tolfenamic acid treatment on Sp1 and VEGF 
promoter in vivo Chromatin Immunoprecipitation was performed as described in 
Materials and Methods.  Chromatin extracted from tumor tissues described in Fig. 34 
were collected and processed. A specific anti-Sp1 antibody and oligonucleotides flanking 
the (A) Sp1, (B) VEGF promoter regions containing Sp1-binding sites was used. Lane 1, 
input chromatin DNA; lane 2, chromatin DNA with control IgG; lane 3, chromatin DNA 
with anti-Sp1 antibody.   
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DISCUSSION  
In this chapter, it was found that metronomic low dose of mithramycin and 
tolfenamic acid combination synergistic down-regulates Sp1 expression, which is 
a key positive regulator of various angiogenic factors expression including VEGF 
and produced synergistic anti-tumor therapeutic effect on xenograft tumor grown 
in nude mice. This therapeutic effect was consistent with Sp1 activity 
suppression and the down-regulation of its downstream angiogenic molecules. 
The experimental results indicate that mithramycin targets Sp1 at its transcription 
level through competition its recruitment on the Sp1 sites. But tolfenamic acid 
promotes Sp1 protein degradation. These findings showed researchers the 
synergistic down regulation of transcription factor Sp1 and would further drive a 
new rational of drug combination to target a protein molecule at different 
biological level. 
Angiogenesis plays important roles in tumor growth and metastasis. Studies 
have been shown that both Sp1 and VEGF are important to pancreatic cancer 
angiogenesis [130, 225]. Currently targeting of VEGF signaling and function is 
still a hot spot in anti- angiogenesis, growth, and metastasis of most tumor type. 
Strategies have been developed, including the use of anti-VEGF antibodies, 
targeting VEGF receptors to directly interfere the signal effect [124, 125]. 
Additionally, multiple genes, identified in pancreatic cancer switch of the 
"angiogenic network" [126, 127], were also proposed to be the anti-angiogenic 
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targets and targeted in experimental mouse model [58, 128]. These reported 
clinical research results and experimental studies using different approaches 
showed the crucial role of the angiogenic process in pancreatic cancer. Also, 
replication deficient recombinant adenovirus mediated was evaluated in human 
pancreatic cancer mouse model and shown to be efficient gene therapy for 
pancreatic carcinoma [129]. 
In methodology, visualized fluorescence imaging was developed in tumor 
angiogenesis research in nude mice based on the stably green fluorescent 
protein expression cancer cell lines and mouse models [234, 235]. Recently, 
multicolored fluorescent proteins were used to develop color-coded fluorescent 
protein imaging models of tumor angiogenesis [236]. The generally termed 
AngioMouse can quantitatively determine efficacy of anti-angiogenesis 
compounds through visualizing the details of the tumor-induced angiogenesis.  
As a regulator of the important pro-angiogenic molecules, Sp1 can be regulated 
by mithramycin through direct competition of Sp1 recruitment on Sp1 sites in Sp1 
promoter as it was shown in last chapter. During the regulation, Sp1 protein level 
change would appear until the mRNA synthesized before mithramycin binds Sp1 
sites, which will take certain time. This is consistent with the observation of 
continuous high dose of mithramycin was needed to obtain significant tumor 
inhibition which leads to the significant cytotoxicity.  Although mithramycin can 
effectively block Sp1 mRNA synthesis, the abundance and strong stability of Sp1 
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protein prevents mithramycin from rapid down-regulation of Sp1 protein in the 
tumor cells. In this chapter, it was demonstrated that tolfenamic acid can promote 
Sp1 protein degradation. More importantly, combined use of mithramycin and 
tolfenamic acid, neither of which has significant effects on Sp1 protein 
expression, led to substantial down-regulation of Sp1 protein, which was 
consistent with a synergistic antitumor effect in mouse models.       
Studies have shown that a number of non-steroidal anti-inflammation drugs have 
anti-angiogenesis activity in a wide variety of xenograft models. Celecoxib and 
tolfenamic acid were shown to decrease pancreatic tumor growth and metastasis 
in nude mice [130, 225]. The drugs activate Sp1, Sp3, and Sp4 protein 
degradation and inhibit VEGF mRNA synthesis and protein expression in 
pancreatic cancer cells. Sp1 was reported to be over-expressed in human 
pancreatic cancer and associated with poor survival [61, 109, 237]. Evidences 
have been provided that transcription factor Sp1 regulates VEGF expression in 
pancreatic cancer cells. In Sp protein family, Sp1, Sp3 and Sp4 are more closely 
related and form a monophyletic group [238]. Experimental results showed that 
through the activation of proteasome-dependent degradation of Sp protein, 
tolfenamic acid exhibited growth inhibitory effect by anti-angiogenic strategy. 
However, down-regulation of Sp1 by mithramycin treatment is mostly involved in 
transcription repression of Sp1 mRNA. Therefore, mithramycin and tolfenamic 
acid have distinct mechanisms of actions in regulation of Sp1 expression and 
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activities, and their interaction forms the molecular basis for their synergistic anti-
angiogenesis and antitumor activities.     
In addition to its anti-angiogenic function reported, down-regulation of Sp1 also 
may cause the altered expression of genes important to cell survival, a 
mechanism that is likely for the antitumor activities of tolfenamic acid and 
mithramycin. For example, tolfenamic acid treatment activates Sp protein 
degradation, decreases Sp proteins binding to survivin promoter and inhibits 
survivin expression in pancreatic cancer cell and subsequently sensitizes the 
pancreatic cancer cell to radiotherapy [239]. Consistently, the data in this chapter 
also shows tolfenamic acid inhibits tumor cell growth in vitro and the effect was 
synergized when combined with mithramycin (Table1, 2 and Figure 28, 29). 
Altered expression of survivin expression may be one of the mechanisms 
underlying the cytotoxic effect of tolfenamic acid and mithramycin. 
Although the data showed tolfenamic acid treatment has minor effect on the 
recruitment of Sp1 on its own and VEGF promoter (Figure 31). Tolfenamic acid 
did affect the Sp1 promoter activity and VEGF promoter activity (Figure 30). The 
possible anti-angiogenic effect of tolfenamic acid may be rely on decreasing total 
Sp1 protein quality but not the interference of the physical contact of Sp1 and its 
binding sites in the promoters which needs to be further investigated.  
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Figure 38 Schematic model of 
mithramycin and tolfenamic acid 
on Sp1  
A, mithramycin treatment physically 
blocks Sp1 binding to Sp1 sites in  
its own and its downstream  
molecules but may leads to a  
negative feedback to Sp1 protein 
degradation  
B, tolfenamic acid treatment facilitate 
Sp1 protein degradation and may  
cause its trans-activation mRNA 
transcription  
C, mithramycin and TA combination  
treatment blocks trans-activation  
and facilitate its degradation which  
blocks the negative feedbacks and  
produce synergistic effect 
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Due to the insoluble character in water, tolfenamic acid was shown to need about 
100 times in concentration to have the similar cell growth inhibition affect in vitro 
(Figure 27). The limit leads to the relatively low therapeutic index. Polymer-drug 
conjugates nanoparticles, one of the major categories of targeted drug delivery 
system, are synthetic water-soluble polymers used as the drug carriers [240]. 
Compare with the corresponding parent drugs, the clinical trial results of polymer-
drug conjugates nanoparticles have several advantages including decreased 
side effects, enhanced therapeutic efficacy, ease drug administration, and 
improved patient compliance. Tolfenamic acid may be more effective by linking 
with nanocarriers, which brings more drugs to the tumor site and reduces 
exposure of normal tissues to the drug.  
As our experimental results showed mithramycin has significant cytotoxicity when 
it produces significant antitumor effect as a single drug using mouse body weight 
change as the measurement. When tolfenamic acid was used together, Sp1 
protein was synergistic down-regulated through different level and tumor growth 
was significant inhibited. But no detectable cytotoxicity was observed. 
Mithramycin nanoparticle has been developed [241]. Polylactide co-glycoide 
(PLGA) based mithramycin nanoparticle inhibited RAW264 macrophages and 
smooth muscle cells and reduced the number of circulating monocytes in rabbits. 
A nanoparticle with homing moiety actively binding to target cell has been widely 
demonstrated. It was shown that the interaction makes more drug compounds 
gathering at the diseased sites, whereas systemic drug exposure was reduced 
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and subsequently minimized cytotoxicity. One category of the homing moieties is 
antibody including intact antibody, fragments (Fab’ or (Fab)2) or genetically 
engineered Fv. In addition to some certain carbohydrates, transferrin was 
proposed as a homing moiety. Compare with antibody, its potential advantages is 
the risk of immune response is rather low because of the present of transferrin in 
organism in high concentrations [242, 243]. The pharmacodynamics and 
pharmacokinetics properties of mithramycin encapsulated by nanoparticle with 
home moiety should be an interesting topic to be investigated. 
As our experimental results showed mithramycin has significant cytotoxicity when 
it produces significant antitumor effect as a single drug using mouse body weight 
change as the measurement. When mithramycin and tolfenamic acid were used 
together, Sp1 protein was synergistic down-regulated through different level and 
tumor growth was significant inhibited. But no detectable cytotoxicity was 
observed. Our data suggested that the combination of mithramycin and 
tolfenamic acid could achieve highest therapeutic index. 
Collectively, our study suggests that mithramycin competing Sp1 recruitment to 
Sp1 sites on both Sp1 and VEGF promoters. Tolfenamic acid does not have the 
competing ability but it down-regulates Sp1 protein level by direct targeting Sp1 
at protein level. The metronomic low dose use of mithramycin in combination with 
tolfenamic acid is a novel strategy of targeting angiogenic molecule Sp1 at both 
transcriptional and protein degradation level. Combining mithramycin and 
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tolfenamic acid in cancer clinical studies could represent a rationale step forward. 
This double targeting from different level strategy would develop 
effective targeted therapy for pancreatic cancer and other cancers. 
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CONCLUSION 
Chapter I of this dissertation demonstrated that knockdown Sp1 protein down-
regulates Sp1 downstream angiogenic factors, significantly reduced pancreatic 
cancer cell angiogenic potential in vitro and led to the angiogenic phenotypic 
change in vivo. All of the experimental results suggest that Sp1 is a key factor for 
pancreatic cancer angiogenesis. 
Chapter II shows that Bevacizumab treatment up-regulates Sp1 and VEGF 
protein in xenograft tumor tissue, which may trigger drug resistance to 
Bevacizumab in turn. This positive feedback mechanism trans-activate Sp1 and 
its downstream angiogenic factors’ over-expression subsequently. Combination 
of mithramycin with Bevacizumab produced synergistic antitumor activity by both 
interposing upstream Sp1 transcriptional regulation and neutralizing downstream 
effecter molecules such as VEGF.  
Chapter III shows the experimental evidence that mithramycin competes Sp1 
recruitment to Sp1 sites on both Sp1 and VEGF promoters. Tolfenamic acid does 
not have the competing ability but it down-regulates Sp1 protein level by direct 
targeting Sp1 protein. The metronomic low dose use of mithramycin 
in combination with tolfenamic acid is an important novel strategy of targeting 
angiogenic molecule Sp1 at both transcriptional and protein degradation level.  
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Collectively, in this dissertation new metronomic anti-angiogenic therapy 
strategies of pancreatic cancer were designed and tested on mouse models. The 
novel findings may provide both theoretical and practical direction to clinic 
practice. The proposed rationales may push the development of effective target 
therapy step forward for pancreatic cancer and other cancers. Hopefully, the 
experimental therapeutic designs may be translated to clinic and benefit 
pancreatic cancer patients in the near future.  
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